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ABSTRACT 
 
During the past decades our knowledge of innate immunology has increased 
drastically. This has improved our understanding about how innate immune cells can 
distinguish self from non-self, commensal bacteria from pathogens, and how it affects 
later adaptive immune responses. This knowledge can lead to new approaches for 
treatment of diseases and autoimmunity, and the development of new vaccines.  
 Vaccines are among the greatest inventions in medical history. However 
traditional vaccine approaches, such as live attenuated or inactivated viruses, have 
failed as vaccine candidates to address certain diseases including HIV/AIDS. Non-
living non-replicating DNA vaccines represent an alternative approach, capable of 
inducing broad cell-mediated and humoral responses, while being safe and fast to 
produce. Still, despite its efficacy in animal models, DNA vaccines have not yet 
succeed to induce effective immune responses in human. To enhance the 
immunogenicity, a combination of more optimized vectors, delivery methods and 
adjuvants will be required. Skin electroporation (EP) is a promising method known to 
elicit robust humoral and CD8+ T cell responses. However, the data on CD4+ T cell 
responses has been limited. In paper I we compare immunization by skin EP with 
intramuscular injection, and find that EP increases both the magnitude and the 
polyfunctionality of the CD4+ T cell responses to the HIV antigen Gag. 
 
In paper II we show that plasmid encoding a secreted flagellin (pFliC) adjuvant 
promotes both humoral and MHC Class I-dependent cellular immunity when 
delivered through different routes representing dermal, systemic, and mucosal tissues. 
Additionally, it enhances mucosal humoral and MHC Class II-dependent cellular 
immunity when delivered mucosally. With in vitro studies we could show that 
secreted pFliC has the ability to activate macrophages through Toll-like receptor 5 
(TLR5), but also cytoplasmic Nod-like receptor C4 (NLRC4), leading to 
inflammasome dependent cell death (pyroptosis). 
  
In paper III we continue to study NLRC4 activation upon recognition of flagellin. 
We have established a system that allows for inducible expression of a NLRC4 
agonist in a macrophage cell line, without additional stimuli. Using this system we 
have shown that NLRC4 induced caspase-1-dependent pyroptosis is independent of 
LPS priming, reactive oxygen species, or classical mitochondrial involvement. 
Nevertheless, pyroptotic macrophages release the alarmin high mobility group box 1 
(HMGB1). Importantly, the functional isoform of HMGB1 is affected by the priming 
event and unprimed pyroptotic cells release a chemotactic form of HMGB1. 
However, priming during pyroptosis causes oxidation of the protein thereby changing 
it to a TLR4-agonist. 
 
Combined, these studies will contribute to the understanding of the regulation of 
inflammasome activity, and how to deliver the next generation of DNA vaccines in 
combination with adjuvants. 
  
	  POPULÄRVETENSKAPLIG SAMMANFATTNING PÅ 
SVENSKA  
 
Den här avhandlingen fokuserar dels på studier av det medfödda immunförsvaret och 
dels på olika sätt att öka effekten av DNA-vacciner. 
 
Under de senaste årtionderna har vår förståelse för hur immunförsvaret fungerar ökat 
drastiskt. Inte minst gäller detta hur det medfödda immunförsvaret känner igen 
patogena bakterier och skiljer dem från den vanliga normalfloran. Celler i 
immunförsvaret uttrycker en uppsättning av olika receptorer som känner igen 
specifika ytstrukturer som är unika för patogena bakterier. En av dessa strukturer är 
flagellin, proteinet som bygger upp de flageller som bakterier använder för att röra 
sig.  
Vaccin är en av de viktigaste uppfinningarna i medicinhistorien och räknat oräkneliga 
liv. Däremot har traditionella vaccinstrategier så som levande försvagat virus eller 
avdödat virus inte varit tillräckligt effektiva för sjukdomar som HIV/AIDS. Nya 
vaccintyper har tagits fram, så som DNA-vaccin vilket är plasmider som bär på gener 
som kodar för delar av viruset, så kallade antigen. Efter vaccineringen tas plasmiden 
upp av kroppens egna celler som skriver av DNA-koden och producerar antigenet. 
Antigenet kan då frisättas från cellerna och aktivera alla delar av immunförsvaret för 
att därigenom utveckla ett försvar mot viruset. DNA-vaccin utgör en säkrare, 
snabbare och potentiellt mer effektiv metod än traditionella vaccin. Dock har metoden 
inte visat sig vara effektiv i människa, trots framgångsrika djurstudier, och behöver 
optimeras. I artikel I har vi jämfört två olika sätt att administrera DNA-vaccin; 
standardmetoden intramuskulär och den lovande metoden intradermal 
elektroporering. Vi har visat att elektroporering ger ett både kraftigare och mer 
kvalitativt immunsvar. 
 Ett ytterligare sätt att optimera vaccin är tillsatts av adjuvans, en tillsats som 
förstärker och förbättrar immunsvaret. I artikel II studerade vi adjuvanseffekten av 
DNA-kodat flagellin när vaccinet administrerades på tre olika sätt: via nässlemhinna, 
via intramuskulär injektion och via huden. Vi visade att flagellin förstärkte effekten 
av vaccinet via alla tre administrationsvägarna. När vaccinet administrerades via 
nässlemhinnan förstärkte flagellin dessutom försvaret i övriga slemhinnor vilket är 
fördelaktigt eftersom slemhinnorna är infektionsvägen för de flesta virus. 
 För att förstå mekanismerna bakom adjuvanseffekten studerade vi hur 
makrofager reagerar på flagellin. Makrofager är en celltyp idet medfödda 
immunförsvaret vars roll är att hitta patogener och visa upp dem för övriga celler i 
immunförsvaret för att på så sätt dra igång ett försvar som kan hantera infektionen. 
Makrofager känner igen flagellin med hjälp av två olika receptorer; Toll-like receptor 
5 (TLR5) som uttrycks på cellytan och Nod-like receptor C4 (NLRC4) inuti cellen. 
Aktivering av makrofagen genom TLR5 gör att cellen producerar signalsubstanser 
som startar valda delar av immunsystemet. Aktivering av NLRC4 medför en 
hopsamling av ett proteinkomplex kallat inflammasom i cellen. Inflammasomen 
klyver de kraftfulla signalsubstanserna IL-1β och IL-18 vilket gör att de kan frisättas 
från cellen. Dessutom inleder inflammasomen en självmordsprocess i cellen som gör 
att cellen dör i så kallad pyroptos. Den här mekanismen gör att bakterier inte kan 
uppehålla sig och föröka sig i cellen. I kastad de ut och kan dödas av andra 
immunceller som lockats till området av de cellstrukturer som frisatts under 
celldöden. I artikel II kunde vi visa att den formen av flagellin som vi använt som 
	  adjuvant hade kapaciteten att aktivera makrofager via både TLR5 och NRLC4, vilket 
kan förklara den breda aktivering av immunförsvaret. 
 I artikel III fortsatte vi att studera NLRC4-inflammasomen i cellkulturer. Vi 
kunde visa att flagellin kan inducera pyroptos oberoende av andra stimuli. Vidare 
kunde vi visa NLRC4-inflammasomen själv inte gav upphov till eller påverkades av 
syreradikaler eller involverade cellens mitokondrier. Det enda som påverkades av 
andra ytterligare stimuli simultant med aktivering av NLRC4-inflammasomen var i 
vilken form varningsmolekylen HMGB1 frisattes i. Eftersom HMGB1 har olika 
funktioner beroende på dess form innebär det celler kan reagera olika på celler som 
dör i pyroptos beroende på vilka stimuli cellen får samtidigt som NRLC4-
inflammasomen aktiveras. Det kan vara värdefull kunskap för att förstå både hur 
immunförsvaret fungerar vid sjukdom och autoinflammatoriska sjukdomar. 
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1. INTRODUCTION 
 
The immune system can be subdivided into the innate and the adaptive immune 
systems. Innate immunity is genetically predetermined and a rapid first line of 
defense, but is limited in its ability to adapt to a changing microbe. As it genomically 
static it does not carry a large memory of pathogenic structures. Responses by the 
adaptive immune system on the other hand develop when a person is exposed to 
pathogens. Although the responses develop slower relative to innate immune 
responses, the adaptive response has the capacity to form immunological memory to 
prevent future reinfection with the same pathogen. Both of these arms are important 
for efficient host defense, and to develop protective vaccines.  
 
The focus of this thesis is pathogen recognition by the innate immune system. 
Specifically, recognition of bacteria by inflammasome complexes that induces 
pyroptosis and cytokine release. The second focus is improvement of plasmid DNA 
vaccines, by adjuvants used to activate the innate immune system and enhanced 
delivery methods. To provide a background, this first part will be an introduction to 
the immune system, with the main focus on innate immunity. This will be followed 
by a presentation of the materials and methods used in this work, and the results 
together with discussion. Also included are the three papers on which this thesis is 
based. 
 
1.1 THE INNATE IMMUNE SYSTEM 
 
Traditionally, innate immunity has been viewed as a fundamental first defense-line, 
pivotal for discriminating self from non-self and friend from foe, but not as specific as 
the adaptive immune system. However, it is a sophisticated system that also has a role 
in orchestrating the adaptive responses. Innate immune responses can be elicited in 
nearly all known cell types. Physical barriers such as the skin and mucosa, as well as 
anti-microbial molecules such as anti-microbial peptides and the complement system 
are also parts of the innate immunity.(1) 
 
To rapidly recognize and identify different classes of invading pathogens and initiate 
responses accordingly, a variety of germ line-encoded receptors specific for 
conserved structures associated with pathogens and general danger molecules have 
evolved. These pattern recognition receptors (PRRs) are expressed by most cell types 
but within the immune system, particularly by the antigen presenting cells (APCs), 
namely DCs and macrophages. PPRs identify pathogen associated molecular patterns 
(PAMPs) that are highly conserved molecular structures shared by large groups of 
microbes, but also danger-associated molecular patterns (DAMPs), typically signs of 
damaged cells, such as extracellular ATP, or a variety of intracellular proteins. 
Various classes of PRRs have been discovered including the Toll-like receptors 
(TLRs), members of the C-type lectin family (CLRs), cytosolic retinoic acid inducible 
gene I (RIG-I)-like receptors (RLRs) and nucleotide oligomerization domain (NOD)-
like receptors (NLRs). 
The CLRs consist of around one thousand members although all of them are not 
involved in recognition of PAMPs. These receptors typically recognize carbohydrates 
that are rich in mannose, fucose and glycan. The downstream result of binding to 
CLRs is often classified as activation of adaptive Th17 or Th1 responses.(2) 
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However, with so many family members, it is likely that they will be found to 
perform other functions as well. 
 RLRs, expressed by most cell types, respond to viral double-stranded RNA 
(dsRNA) in the cytosol. RLR binding of dsRNA from virus such as Flavi viruses, 
influenza and Epstein-Barr. Generally, they have been observed to initiate signaling 
through NF-kB and Interferon Response Factor 3 (IRF3) leading to the production of 
pro-inflammatory cytokines and Type-I and III IFNs.(3)   
 
This thesis is built around the recognition of the PAMP flagellin by NLRs and TLR5, 
the introduction will therefore focus on these receptors and how they affect immune 
responses.  
1.1.1 TLRs  
 
The most well studied PRRs are the TLRs, first discovered in 1985. Today, there are 
10 known TLRs in human beings and 13 in mice (4). The TLRs are class I 
transmembrane proteins found both on the cell surface (TLR1, -2, -4, -5, and -6) to 
detect various PAMPs and others are found in the endosome (TLR3, -7, -8, and -9) 
where they can detect viral PAMPs or bacterial nucleic acids.  
 The receptors consist of extra-cellular ligand binding leucine-rich repeat 
domains (LRRs) and cytoplasmic TLR signal domains known as Toll/IL-1 receptor 
(TIR) domains that transduce the signals through interactions with cytoplasmic 
adaptor proteins.(5) TLRs are expressed as dimers in a low-affinity complex and can 
form both homodimers and heterodimers, for example TLR1/TLR2. Once the ligand 
binds, a conformational change brings the two TIR domains closer together, allowing 
for interaction with adapter proteins.(5) The adapter protein is in most cases MyD88, 
which activates a signaling cascade ending with activation of transcription factors 
(NF-κB and/or AP-1) and phosphorylation of for example interferon regulatory 
factors (IRFs), which activates the type I IFN promoters. The MyD88 independent 
exceptions are TLR3, which recruits only TRIF, and TLR4 that can utilize both 
MyD88 and TRIF as adaptors. TRIF signaling and RIP kinases leading to up-
regulation of NF-kB-inducible cytokines and phosphorylation of IRF-3. The TRIF-
signaling pathway is activation production of both NF-kB induced release of 
cytokines and type I and type III IFNs.(4, 6)  
 
1.1.2 NLRs, caspases and inflammasomes 
 
The nucleotide-binding domain leucine-rich repeat containing (NLR) family 
represents the largest group of intracellular PRRs. To date it is compromised of 22 
human genes and 34 mouse genes.(7) Similar to TLRs, the NLRs contain three 
domains. All NLRs share a common central nucleotide-binding and oligomerization 
(NACHT) motif, enabling for activation of the signaling complex through ATP-
dependent oligomerization. This domain is typically flanked by C-terminal LRRs, 
thought to function in ligand sensing and to modulate NLR activity through auto-
repression (8). The N-terminus contains either a caspase recruitment (CARD) domain, 
a pyrin (PYD) domain or a baculovirus IAP repeat (BIR) allowing for recruitment of 
adaptor proteins, typically caspase-1 and apoptosis associated speck-like protein 
containing a CARD (ASC). 
The NLRs can be divided into three phylogenetic subfamilies (9). Members of the 
nucleotide-binding oligomerization domain (NOD) subfamily (NOD1-2, 
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NOD3/NLRC3, NOD4/NLRC5, NOD5/NLRX1, CIITA) have diverse functions 
including acting as co-activators and NF-kB activating platforms. The remaining two 
groups consist of NLRs known to be involved in inflammasome formation. The 
NLRP (NACHT, LRR and PYD domains-containing protein) subfamily include 
NLRP1-14, while the IPAF subfamily consists of NLR family CARD domain-
containing protein 4 (NLRC4) and Neuronal apoptosis inhibitory protein. 
 
Shortly after the discovery of the NLRs, they were hypothesized to recruit caspases, 
because of their CARD/PYD domains. Caspases are cystein proteases that are most 
known to have essential roles in apoptosis, but they can also induce inflammation. 
Dogmatically speaking, caspases are categorized into proapoptotic (caspase-2, -3, -7, 
-8, -9 and -10) and proinflammatory (caspase-1, and -11 in mouse and caspase-1, -4, 
and -5 in human)(10). The best characterized proinflammatory caspase is caspase-1. It 
is a rather promiscuous protease, highly expressed in leukocytes, monocytes and 
epithelial cells (11) which is best known to process IL-1β and to induce a form of 
regulated cell death called pyroptosis (8). Similar to most other caspases, caspase-1 is 
synthesized as an inactive monomeric zymogen and acquires proteolytic activity upon 
dimerization and autoproteolytic processing into the subunits p20 and p10 (12, 13). 
Notably, and important to remember in the context of this thesis, this processing step 
is not required for the induction of pyroptosis (14). 
 
In 2002 Martinon et al demonstrated that NALP1 recruited and activated caspase-1 
and 5, leading to release of active IL-1β and IL-18 as well as initiation of pyroptosis 
(8). The caspase-1 activation was dependent on assembly of a large protein complex 
(700 kDa), containing caspase-1, NALP1 and ASC. The protein complex was termed 
inflammasome because of its similarities with the apoptosome and the term was 
subsequently broadened to describe further caspase-1 recruitment platforms. So far, 
the NLR family members reported to be part of inflammasomes are: NLRP1b, 
NLRP3, NLRC4/NAIP5 (10) and more recently NLRP6 (15) and NLRP1a (16). In 
addition to these, certain non-NLRs can also induce inflammasome assembly, namely 
the DNA sensor absent in melanoma 2 (Aim2)(17) and the RLR receptor retinoic acid 
inducible gene I (RIG-I)(15) (18). (Figure 1) Other candidates for inflammasome 
formation based pilot studies are NLRC5(19) and NLRP7 (20). Inflammasome 
function has been observed mainly in myeloid cells, but also in nonmyeloid cells such 
as keratinocytes and astrocytes.(21, 22) Importantly, numerous other cell types also 
express inflammasome components but their role in immunity and disease is poorly 
studied. 
 Upon detection of their respective ligands, ASC is recruited to the NLR 
through PYD or CARD interactions. Because ASC contains both a PYD and a 
CARD, it can oligomerize with certain NLRs to form a cytosolic structure, and also 
recruit caspase-1. The CARD containing NLRs can recruit caspase-1 directly whereas 
the PYD containing NLRs are totally dependent on ASC. This does not mean that 
ASC may not have affects on CARD containing NLRs. It has been observed that the 
presence of ASC could influence the function of CARD containing NLRs(23). 
However, currently how this could occur is poorly understood. 
 The NLRP1a assembles in response to LCMV and 5-fluorouracil, NLRP1b to 
inflammasome anthrax lethal toxin (24), Aim2 is activated by dsDNA (17) and RIG-I 
responds to certain RNA viruses such as VSV and serves as a dual sensor that can 
trigger both NF-kB-dependent expression of pro- and inflammasome activation(18). 
The ligands and signaling pathways for NLRP6 are less clear. It contributes to 
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protection against colitit, colorectal tumorigenesis and non-alcoholic steatosis by 
regulating the gut epithelia and microflora.(25,26) However, mice with NLRP6 are 
less resistant to bacteria such as S. typhimurium and Listeria monocytogenes.(27) It 
does appear that various agonist are able to activate the same, or similar NLR family 
members which makes it difficult to understand the precise molecular mechanisms of 
how these systems work. Nevertheless, these systems may play a key role in the 
sensing of infection and cell stress and further work is warranted. 
  
 
 
Figure 1: The currently established inflammasomes. 
 
IL-1β is a powerful inflammatory mediator contributing to acute systemic and local 
inflammation by inducing fever, recruitment of leukocytes and promoting adaptive 
immune responses.(28) However, IL-1β also contributes to several chronic conditions 
and must be rigorously controlled at several levels. First, triggering of TLRs is 
required for expression of the precursor form, which accumulates in the cytosol until 
it, secondly, is cleaved into its mature release form. The mature IL-1β lacks a 
conventional secretion signal(29), and it is not secreted through the standard Golgi-
ER pathway, but its release is controlled by a poorly understood mechanism.(Further 
discussed in section 4.4) Additionally, an endogenously produced and secreted IL-1 
receptor antagonist (IL-RA) can also regulate IL-1ß action after release indicating an 
important biological need to control this inflammatory mediator. 
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 In contrast to pro-IL-1β, pro-IL-18 is constitutively expressed and apparently 
does not rely on priming. Its function after release depends on the cytokine 
environment. In presence of IL-12p40, IL-18 induces production of INF-γ by T and 
NK cells, thereby promoting Th1-like responses. In the absence of IL-12, it instead 
induces production of IL-4, IL-5 and IL-10, thereby promoting a Th2-like response. It 
is also known to synergize with IL-23 to enhance the IL-17 production from Th1 
cells. Additionally, IL-18 can stimulate the synthesis of nitric oxide (NO) and reactive 
oxygen species (ROS) as well as induce expression of other cytokines, chemokines, 
and cell adhesion molecules.(30-32). Importantly, there are reports of the importance 
of caspase-1-dependent IL-18 production in protective immunity against pathogen 
infection. For example, protection against S. flexneri infection is controlled by IL-18, 
not IL-1β (33).  
 
In addition to caspase-1, its homologue caspase-11 (in human caspase-4) has been 
presumed to have a role in inflammasome function. Studies of the impact of caspase-
11 have been difficult since caspase-1 and -11 are too close in the genome to be 
segregated by homologous recombination and furthermore, caspase-11 is 
dysfunctional in strain 129 mice. A strain of mouse commonly used to generate 
genetic deficiencies. Hence, the Casp1-/- developed using 129 mouse embryonic stem 
cells used in many publications also lack caspase-11 (34). Lately new mice have been 
generated and caspase-11 has been reported to have a crucial role in alternative 
inflammasome activation called the non-canonical inflammasome pathway. 
Activation of this non-canonical pathway is essential for inflammasome response to 
Escherichia coli, Citrobacter rodentium, Vibrio cholerae, cholera toxin B(34) as well 
as S. typhimurium (35) and its defense against cytosolic, but not vacuolar 
bacteria.(36). Cell death induced by this pathway is independent of NLRC4/NLRP3 
and caspase-1. IL-1β processing on the other hand requires NLRC4/NLRP3, and is 
impaired in the absence of caspase-1 (34, 35). Furthermore, LPS toxicity has been 
shown to be dependent on caspase-11 rather than caspase-1, suggesting that caspase-4 
in human may be better targets than caspase-1 in sepsis treatment (34, 37). 
Additional molecules have been reported to modulate inflammasome activation. 
NLRC4 activity requires phosphorylation by the kinase PKCδ between the NACHT 
and LRR domain in response to S. typhimurium (38). NLRP3 activity, and possibly 
also other inflammasomes, is dependent on Protein Kinase R (PKR). PKR interacts 
with all known parts of the inflammasome complex and mutant PKR carrying a 
Lys296Arg mutation lacking kinase activity, fails to activate the NLRP3 
inflammasome (39). This finding has however been contradicted in a later publication 
(40). The thioredoxin-interacting protein (TXNIP), a protein linked to insulin 
resistance, has been identified as a redox-sensitive ligand of NLRP3 (41). NLRP3 
inflammasome activators trigger binding of TXNIP to NLRP3 and its activation is 
impaired in mice deficient in TXNIP (41). However, these results have not yet been 
confirmed by other groups (42). 
 
1.1.2.1 NLRP3 
 
NLRP3 is the most well characterized inflammasome, activated by a broad range of 
stimuli utilizing a two-step mechanism. As NLRP3 is not expressed in resting cell, it 
requires a NF-kB-dependent priming event as a first signal (43). The second signal 
can be mediated by a great variety of stimuli, such as ATP, bacterial pore-forming 
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toxins (44), urate crystals (45), asbestos and silica (46), muramyl dipeptide (MDP) 
(47, 48), bacterial DNA and RNA, viral RNA and imidazoquinolone antiviral 
compounds(49,50), components of fungal cell wall such as zymosan and mannan 
(51), the adjuvant Alum (52), and cholesterol (53) LPS alone has also been used to 
activate the NLRP3 inflammasome but IL-1β is then processed very inefficiently (54, 
55). It can also be discussed if the activation is due to LPS itself or ATP/mtDNA 
release caused by LPS stimulation or in some cases contaminating agonists such as 
MDP (47). However, LPS-priming alone can induce capase-1 activation in 
macrophages genetically deficient in XIAP, cIAP1 and cIAP2 (56) and it is possible 
that variations in their expression or function may affect inflammasome activation.  
 Even with all these different activators, no direct ligand binding has been 
observed and how NLRP3 detects the ligands is incompletely understood. Although 
the precise mechanism of NLRP3 activation is still debated, it is suggested to involve 
K+ efflux (57,58), reactive oxygen species production (9,59), lysosomal disruption 
(60), mitochondria dysfunction (61, 62) and to be dependent on intrinsic apoptosis-
mediated loss of the mitochondrial inner membrane potential, leading to release of 
oxidized mitochondrial DNA that activates the NLRP3 inflammasome (63). It may 
also be dependent on a combination of these factors. As NLRP3 has a PYD domain it 
is dependent on ASC for recruitment of caspse-1. Furthermore, the activation is 
thought to be controlled by ASC, microRNA, ubiqutination, phosphorylation and 
calcium.(64) 
 
In conclusion, activation of the NLRP3 inflammasome is a potent response to various 
stimuli of both bacterial, endogenous, and particle origin. Because of the diversity of 
the agonists, the need for a priming signal may be of importance to avoid auto-
inflammatory states. Although the NLRP3 inflammasome has been extensively 
studied, there are still new agonists being reported and many questions remain. For 
example, the mechanisms for recognition of ligands and how they induce the 
inflammasome assembly is generally unknown. Furthermore, even though "the 
inflammasomes" are being grouped together as caspase-1-activating platforms, new 
knowledge regularly reveals their functional differences. 
 
1.1.2.2 NLRC4 
 
NLRC4 is expressed in myeloid cells, with exceptions including neutrophils, but also 
additional cell types including intestinal endothelial cells (65, 66). It is activated by 
cytosolic flagellin, the monomer of the bacterial swimming device flagella, present in 
most Gram-negative and Gram-positive bacteria.(67, 68) Additionally it responds to 
components of the bacterial type III and type IV secretion systems (T3SS and T4SS). 
These systems are major virulence factors in most Gram-negative bacteria and 
function to transfer effector proteins from the bacteria into the host's cytosol. The 
secretion apparatus attaches to the bacteria with basal rod proteins and forms a hollow 
needle complex that spans the bacterial membrane. Mouse NLRC4 recognize rod 
proteins from bacteria including S. typhimurium (PrgJ), Burkholderia pseudomallei 
(BsaK), E. coli (EprJ and EscI), S. flexneri (MxiI), and Pseudomonas aeruginosa 
(PscI).(69, 70) All of these components share sequence and structural similarity(69, 
71). Flagellin is typically transferred into the cytoplasm through the bacterial 
secretion system. For example activation of NLRC4 by S. typhimurium does not only 
require flagellin, but also a functional T3SS (68, 72-74). However, purified flagellin 
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monomers can also be sensed by NLRC4, suggesting that at least some cells have the 
means of cytosolic uptake of free flagellin(75). 
 In contrast to NLRP3, NLRC4 is constitutively expressed and can be activated 
by flagellin without the need of a priming signal.(59) (paper III). Furthermore, it has 
a CARD domain and can recruit caspase-1 and initiate pyroptosis independently of 
ASC (76), although the IL-1β production is severely impaired in the absence of ASC 
(77).  
 
NLRC4 agonists are not sensed directly by NLRC4 but instead bind members of the 
BIR domain containing NLR family apotosis inhibitory protein (NAIP) family 
members. In mice, NAIP5 and probably also the closely related NAIP6, can directly 
bind flagellin (70, 78) while the rod proteins are recognized by NAIP2 (70). Ligand 
binding promotes a physical association between NAIP5/6 and NLRC4 resulting in 
assembly and activation of the inflammasome complex (70, 78, 79). 
 The mouse genome encodes seven NAIP proteins while the human only 
harbors one, a fact that did concern researches for some time. Recently, the human 
NAIP has been shown to also recognize components from bacterial secretion system, 
to subsequently induce NLRC4 inflammasome activation. Needle subunits from the 
T3SS of S. typhimurium as well as EHEC, B. thalandensis, P. aeruginosa, S. flexneri 
can interact with the human NAIP indicating that it can function in a similar way as 
the mouse NAIP5(6)/2. There appears to be a broad conservation between the human 
and mouse NAIPs in terms of structural recognition and biological function, even 
though the exact ligands and receptors differ (70, 78). 
 
In conclusion, NLRC4/Naip5 activation is clearly a rapid and important defense 
against intracellular bacteria. It is in some ways better understood than the NLRP3 
inflammasome, since there is a defined ligand binding triggering assembly. However, 
there are still many questions remaining regarding its regulation and the induction of 
pyroptosis. For example, how caspase-1 functions to execute pyroptosis without being 
proteolytic processed. 
 
1.1.3 Flagellin 
 
Flagellin has been known to induce innate immune responses since 1998, when it was 
reported that it was a potent inducer of cytokines from human monocytes (80). Later 
on it was established that flagellin rapidly induces activation of IL-1R-associated 
kinase 1 and the receptor for extracellular flagellin was found to be TLR5(81, 82). 
Intracellular localized flagellin signals via NLRC4/NAIP5 (67, 68, 71) and the 
distinct domains required for these interactions are completely separate from those of 
TLR5. Most flagellin monomers have four domains (D0, D1, D2 and D3) and are 
shaped as a bent hairpin, with the D3 domain forming the looped end of the hairpin 
and the D1 and D2 regions comprising the arms. The D0 and D1 domains are 
conserved and while the D2 and D3 domains are highly variable in primary sequence 
and length can be used to discriminate different bacteria. The D1 portion of the 
conserved C- and N-terminal domains of flagellin is required for binding to TLR5 
(83, 84). This binding can be abolished by an mutation at residue I411A but 
conformational changes can also abolish binding (85). The interaction of flagellin 
with NLRC4/Naip5 instead requires the 34-35 amino acid long tail at the C-terminal 
end of the D1 portion (71) (paper III). Specific residues within this tail are also 
required for activity (86). 
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 Properties of flagellin are studied in two of the papers in this thesis. In paper II 
we evaluated the adjuvant properties of DNA-encoded flagellin, and in paper III we 
focused on flagellin-induced activation of the NLRC4 inflammasome.  
 
1.1.4 Microbial inflammasome evasion 
 
To survive in the host, pathogens have acquired sophisticated mechanisms to interfere 
with the host responses to infection. Pathogen-mediated control of inflammasome 
recognition can allow for intracellular replication and reduced influx of immune cells. 
For such evasion strategies, all stages of the inflammasome function can be targeted. 
S. typhimurium encodes two distinct T3SS that promote different virulence aspects. 
During the infection phase it expresses the Salmonella pathogen island 1 (SPI1) T3SS 
including the rod protein PrgJ, which is recognized by NLRC4. To avoid recognition 
during the systemic phase and promote intracellular replication, this T3SS is later 
repressed and replaced by the SPI2 system including the rod protein Ssal, which is not 
recognized by NLRC4 (68, 87, 88). Similarly, Yersinia enterocolitica shuts down its 
flagellin expression in temperatures above 37°C (89). Other bacteria such as EPEC, 
C. violaceum and B. thailandensis express flagellin unable to bind NAIP5 and can 
thereby evade detection (70). These escape mechanisms may be one reason to the 
slightly redundant recognition of bacterial structures by the inflammasomes (90). 
 Yersinia also produces a set of T3SS effector molecules called Yop proteins. 
The Yops can hijack intracellular machinery in order to interfere with the 
inflammatory response and phagocytosis. YopE and YopT prevent oligomerization of 
caspase-1 by interfering with certain Rho GTPase proteins, thereby disassembling the 
actin skeleton. Rho GTPases regulate the intracellular actin dynamics, which 
somehow is involved in caspase-1 activation. YopE acts as a GTPase-activating 
protein, switching off Rho GTPases by accelerating GTP hydrolysis, while YopT acts 
as a cystine protease and inactivates Rho GTPases by cleaving of their C-terminal 
prenyl membrane anchor (91). More recently, YopK of Y. pseudotuberculosis was 
shown to associate with the T3SS translocon to mask its detection by the 
inflammasome (92). 
 Infections with Mycobacterium tuberculosis (Mtb) or the vaccine strain 
Mycobacterium bovis (BCG) are associated with low levels of IL-1β. One reason may 
be that BCG produces a Zn2+ metalloprotease that inhibits processing of IL-1β by a 
currently unknown mechanism (93). 
 In contrast, S. flexneri and S. typhimurium can also activate the inflammasome 
and utilize the ensuing inflammation for invasion and disease progression. Caspase-1-
deficient mice confer resistance to these bacteria (94-96). 
Viruses also have strategies to evade detection by the inflammasome. Common viral 
strategies are to mimic the host suppression of the inflammasomes, to target 
especially ASC and caspase-1. Certain Pox-viruses have a PYD containing protein 
analogous to the host's cPOP proteins (97) that bind ASC to prevent inflammasome 
IL-1β processing. Additionally Poxviruses produce viral serpins analogous to the 
mammalian protease inhibitor 9 (PI-9) protein. PI-9 is constitutively expressed in 
vascular smooth muscle cells and prevents processing of pro-IL-1β and pro-IL-18 by 
blocking the active site of caspase-1 (98). The best known inflammasome inhibitor is 
the cowpox gene CrmA, which is a potent inhibitor of Caspase-1 and -8 (99). Other 
viral caspase-1 inhibitors are NS1 from influenza A viruses which inhibits PKR and 
type I interferon response, and the apoptotic protein pR35 from baculovirus (100). 
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Microbes have evolved to escape the inflammasomes in many different ways. Some 
use strategies to avoid recognition or inhibit involved proteins while other take 
advantage of the system. An improved understanding of their evasion mechanisms 
and hijacking is necessary for both better prevention and treatment of infections. 
Mimicking the mechanisms may also be an option to control inflammasome 
regulation.  
 
1.1.5 Deregulation of inflammasomes  
 
Inflammasome activity is important for clearance of bacteria and viral defense, but 
when dysregulated, it can cause autoimmune diseases. Gain of function mutations in 
the gene coding for NLRP3 are associated with a group of autoinflammatory diseases 
collectively termed cryopyrin-associated periodic syndrome (CAPS), characterized by 
cyclical periodic fever and inflammation due to increased NF-kB signaling, caspase-1 
activation and production of IL-1β (101, 102). More than 70 inherited and disease-
associated mutations have been identified so far, most of them are situated within and 
around the NLRP3 NACHT domain (103). Fortunately, CAPS patients with excessive 
IL-1β production have benefited from IL-1 neutralizing therapies(104, 105). Another 
mutation in NLRP3 has been associated with increased susceptibility for Crohn's 
disease and inflammatory bowel disease (IBD)(106). Mice lacking NLRP3 and ASC 
are protected from EAE and this is associated with reduced Th1 and Th17 responses 
(107,108). Similarly, mutation in NLRP1, reducing the threshold for inflammasome 
assembly, increases the incident of vitiligo and Addison's disease (109). There are 
currently no reported cases of mutations in NLRC4. 
 
Dysregulation of IL-1β is also implicated in the pathophysiology of several common 
diseases including atherosclerosis, osteoartritis, metabolic syndrome, gout and type 2 
diabetes. This is partially because NLRP3 causes inflammation when activated by 
crystals such as cholesterol crystals, involved in atherosclerosis, urate crystals, known 
to cause gout, and islet amyloid polypeptide, a hormone secreted together with 
insulin. Additionally, TXNIP, a protein upregulated by glucose and linked to insulin 
resistance, has been suggested to activate NLRP3. IL-1β is further involved in 
impairment of both insulin signaling and promotes beta-cell dysfunction and cell 
death (110-112). 
 Also other diseases with an inflammation aspect involve inflammasome 
activity. Both acute brain injuries such as stroke and chronic neurodegenerative 
diseases, including Alzheimer's, are exacerbated by inflammation and IL-1. Mice 
deficient in caspase-1 show reduced infarcts after stroke, and reduced brain injury. 
These mice also get reduced endotoxemic acute real failure, although neutralization of 
IL-1β and IL-18 has little protective effect (11). 
 
In conclusion, dysregulation of not only cytokine secretion but also cell death, can be 
devastating. Overactive NLRP3 inflammasome is involved in various autoimmune 
diseases, however also other inflammasomes can cause harm.  
 
1.2 CELL DEATH 
 
For many years the death of mammalian cells was based on a simple dichomoty: 
death by programmed apoptosis or uncontrolled necrosis. This two-sided view of cell 
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death no longer holds true and there are many defined mechanisms able to activate 
cell death. The first descriptions of programed cell death mechanisms were done in 
the mid 1960s and based on morphology. Today morphology is not the only 
parameter used to classify cell death but also biochemical and molecular techniques 
are required. Using new techniques there is also a new understanding of the 
complexities of cell death leading to newer and more diverse classifications. In 2009, 
the Nomenclature Committee on Cell Death (NCCD) proposed recommendations for 
classifications for the following forms of death: Anoikis, autophagic cell death, 
caspase-dependent intrinsic apoptosis, caspase-independent intrinsic apoptosis, 
cornification, entosis, extrinsic apoptosis by death receptors, extrinsic apoptosis by 
dependence receptors, mitotic catastrophe, necroptosis, netosis, partanatos, and 
pyroptosis (113). The work of this thesis addresses mainly pyroptosis. However, to be 
able to draw distinctions between pyroptosis relative to apoptosis and necroptosis, a 
brief introduction to all three forms of cell death is needed.  
 
1.2.1 Apoptosis 
 
Apoptosis is a form of regulated cell death used for organ shaping during embryonic 
development and homeostasis in adults, as well as a suicide program for damaged 
cells. Apoptosis is dependent on caspase cascades but the induction can be divided 
into extrinsic and intrinsic apoptosis. Generally, the apoptotic caspases are divided 
into "initiator caspases" (caspase-2, -8, -9, and -10) and ‘‘executioner caspases’’ 
(caspases-3, -6, and -7). Morphologically, apoptosis is characterized by blebbing of 
the plasma membrane, and the formation of 'apoptotic bodies'. The chromatin in the 
nucleus undergo an irreversible condensation, after which the nucleus breaks up into 
fragments (114, 115). The chromosomal DNA is cleaved into characteristic fragments 
pattern by caspase-activated DNase (CAD), which is activated when its inhibitor 
ICAD is cleaved off by caspases (116, 117). 
 
1.2.1.1 Intrinsic apoptosis 
 
Intrinsic apoptosis is induced by signals such as DNA damage, high oxidative stress, 
cytosolic Ca2+ overload, ER stress and other diverse triggers. As the triggers are quite 
variable, the signaling cascades also appear to be highly heterogenous. However, all 
these responses eventually end up affecting the mitochondria. Both pro-apoptotic and 
anti-apoptotic signals converge at the mitochondrial membrane. When the pro-
apoptotic signals dominate, mitochondrial outer membrane permeabilization (MOMP) 
occurs due to the activation of pore-forming pro-apoptotic members of the Bcl-2 
family, or through opening of the permeability transition pore complex in the inner 
mitochondrial membrane. MOMP has multiple lethal consequences, such as 
dissipation of the inner mitochondrial transmembrane potential, inhibition of the 
respiratory chain and release of toxic proteins such as AIF, SMAC/DIABLO and 
Cytochrome C. Cytosolic Apaf-1 senses the release of its ligand, cytochrome C, 
which binding triggers oligomerization. This complex, "the apoptosome", recruits 
caspase-9, which initiates the caspase cascade to apoptosis.(118) 
 
 
 
1.2.1.2 Extrinsic apoptosis 
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Extrinsic apoptosis is induced by extracellular signals. It is triggered by binding of 
ligands such as FAS/CD95 ligand, tumor necrosis factor a (TNFa) and TNF (ligand) 
superfamily TNF-related apoptosis inducing ligand (TRAIL) to their respective so-
called death receptors. A signal can also be dispatched by the 'dependence receptors' 
including netrin receptors, which can exert lethal functions when their ligands fall 
below a threshold level. When FAS binds its ligand FASL, the assembly of FAS 
subunit trimers are stabilized leading to a conformational change that allows for 
formation of a multiprotein complex at the cytosolic tail of the receptor. This 'death-
inducing signaling complex' (DISC) consists of the death domain (DD), shared by all 
death receptors, and proteins such as receptor-interacting protein kinase 1 (RIP1), 
different forms of apoptosis inhibitors, E3 ubiquitin, and FAS-associated protein with 
a DD (FADD). The DISC complex serves as a platform for recruitment and activation 
of pro-caspase-8 and -10 as well as degradation of RIP1 and RIP3.(117-119) 
 
Cell types that perform extrinsic apoptosis can be divided into 'type I and II cells'. 
Type I cells, which includes lymphocytes, can activate caspase-8 directly after DISC 
formation to catalyze maturation of caspase-3, thereby triggering the execution phase 
of apoptosis in a mitochondria-independent manner. In type II cells, including 
hepatocytes and B cells, caspase-8 instead mediates cleavage of BH3-interacting 
domain death agonist (BID) after DISC formation to generate the mitochondrion-
permeabilizing fragment truncated BID (tBID). Hence, extrinsic apoptosis in type I 
cells is mitochondria-independent, even though tBID and MOMP can occur, while in 
type II cells it is associated with MOMP including the dissipation of mitochondrial 
transmembrane potential.(118, 119) 
 
1.2.3 Pyroptosis 
 
Pyroptosis was first described in macrophages infected with S. flexneri and soon 
thereafter also with S. thyphimurium (120-122). Pyro, the Greek word for fire, refers 
to the heat caused by IL-1β induced fever and -ptosis to its similarities with apoptosis 
(123). Even though several features of pyroptosis appear to overlap with apoptosis, 
this is a distinct form of regulated death with distinct mechanisms and morphology. 
So far, pyroptosis has mainly been studied in macrophages and dendritic cells. 
However, it has also been observed in for example epithelial cells (124, 125) and as 
also other cell types express inflammasome components, pyroptosis may occur in 
some capacity in additional cell types.  
 Pyroptotic cell death is dependent on caspase-1, but appears not to involve 
apoptotic caspases (121, 126, 127). Caspase-1 has the ability to process the apoptotic 
caspase-3 and -7 and has been observed to do so during pyroptosis (126, 128, 129). 
However, the pyroptotic events are not affected by the lack of these caspases(126, 
128) even though caspase-7 is important in the defense to Legionella pneumophil 
a(129). A possible explanation for the lack of involvement of caspase-3 and -7 is that 
their processing is a late event that gets preceded by the more rapid death program. 
 
While the classic morphological features apoptotic cells are cell shrinkage and 
blebbing, the pyroptotic events are proposed to lead to the formation undefined pore 
formation in the plasma membrane causing a net increased osmotic pressure, water 
influx and cell swelling (116, 130). This process can be delayed by extracellular 
osmoprotectants such as high extracellular K+ or by extracellular glycine(121, 130). 
Similar to apoptosis, chromosomal DNA is cleaved into fragments during pyroptosis 
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(131) and the cells are positive using TUNEL assay (120, 121) although, the DNA is 
not laddered in the same pattern as in apoptosis (116). The DNA degradation is 
followed by nuclear condensation but in contrast to apoptosis, the nuclear integrity 
remains intact (116). The mechanisms of DNA degradation are unclear, and cleavage 
of certain target proteins characteristic for apoptosis is still discussed. For example, 
poly (ADP-ribose) polymerase 1 (PARP1) and ICAD are cleaved in some studies but 
remain intact in other (116, 128, 130, 132). 
 
Pyroptotic cell death is implicated in clearance of pathogens by four mechanisms. It 
1) eliminates the intracellular niche required for bacterial replication 2) leads to 
release of intracellular content that function as DAMPs recruiting immune cells  
3) releases surviving bacteria for destruction by recruited neutrophils (87) and  
4) releases mature IL-1β and IL-18. The importance of pyroptosis as a host-defense 
mechanism is highlighted by observations that IL-1β and IL-18 are not required for 
caspase-1-dependent clearance of several bacteria such as Legionella pneumophila, 
Burkholderia thalandensis, and S. typhimurium that are modified to constitutively 
express flagellin (87). Caspase-1 deficient mice are also more susceptible to 
Francisella tularensis than mice deficient in both IL-1β and IL-18 (133). 
Furthermore, mice lacking both IL-1β and IL-18 are still susceptible to endotoxic 
shock, whereas mice deficient in caspase-1 are protected. This indicates that the 
endotoxic shock is mediated by other DAMPs released from the lysed cells, such as 
high-mobility group box 1 (HMGB1) (134). Alternatively, the endotoxic shock may 
be mainly dependent on caspase-11, which does not release much IL-1β/IL-18 (34). 
  
Pyroptosis is not only involved in immune responses during bacterial infection. 
NLRP1a-induced pyroptosis plays a role regulating hematopoietic progenitor cells, by 
restricting their proliferation and enable self-destruction of infected cells to limit 
dissemination of infection during their proliferation and maturation. On this recent 
work, mice with mutated hyper-responsive NLRP1a develop leukopenia in the steady 
state and LCMV infection or chemotherapy causes prolonged cytopenia, bone marrow 
hypoplasia, and immunosuppression. These reactions are independent of IL-1β but 
could be caused by NLRP1a triggered pyroptosis and depletion of hematopoietic stem 
cells in the bone-marrow stroma.(16) 
  
In summary, inflammasome induced pyroptosis is a rapid caspase-1-dependent type 
of cell death, accompanied by release of IL-1β, IL-18 and putative mix of other 
DAMPs. The different inflammasome can together recognize a diversity of stimuli 
and initiate pyroptosis. There are still many unanswered questions about how 
inflammasomes and pyroptosis are regulated and when their responses are beneficial 
or not. 
 
1.2.4 Regulated necrosis/necroptosis 
 
Necrosis was for a long time considered as an accidental fully uncontrolled death 
mode. This paradigm started to be challenged in 1988 when it was discovered that 
cells can respond to TNF-α by dying in two different ways, either showing typical 
apoptotic or a more necrotic morphology. It is now clear that necrosis can occur in 
regulated manner and have both physiological and pathological functions. The cells 
have morphological features of necrosis, but the cell death can be regulated by a 
signaling pathway associated with activation of receptor interacting protein (RIP) 
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kinases.(135, 136) Necrosis can be triggered by stimuli such as DNA damage, 
physical damage, PRRs and hypoxic conditions but also ligation to death receptors 
including TNFR1, TNFR2, Fas and TRAIL (135, 136). When necrosis is induced by 
ligand binding to death receptors it is termed 'necroptosis'. This ligand binding is best 
known to initiate extrinsic apoptosis but if the apoptosis pathway is inhibited, the 
response can be shifted to necroptosis (135, 137). In the final stage of initiation of 
apoptosis, caspase-8 is activated to inactivate RIP1 and RIP2 and to initiate the 
caspase cascade. However, if caspase-8 is inhibited, the so-called necrosome complex 
is formed instead. This phosphorylation complex contains FADD, RIP1 but also RIP3 
and initiate the necroptosis signaling cascade.(135, 138, 139) 
 
Necroptosis is now considered to be a major cell death pathway regulating both 
development and immunity(140). RIP-1 deficient mice display extensive apoptosis 
and die soon after birth (141). Even though the necroptotic morphology appears 
similar to uncontrolled necrosis, this is clearly a form of regulated cell death since 
necroptosis is 1) induced by defined ligands 2) can be inhibited by inhibiting proteins 
in the signaling cascade, for example RIP1 or RIP3 3) involves degradation of 
intracellular content. It is an important exit strategy when apoptosis caspases are 
inhibited, by for example S. typhimurium, known to down-regulate caspase-8 (142) 
but necroptosis likely also has other functions and more is to be revealed.  
 
1.2.5 Coping with dying cells - Find them and eat them  
 
The body has a turnover of over one billion cells every day. These cells fall into 
different classes depending on type of cell death and cell type and need to be handled 
at the time. Apoptosis is generally a non-inflammatory type of cell death since the 
cytoplasmic content is contained/shielded by packing in 'apoptotic bodies' and cleared 
up by macrophages. However, apoptotic cells need to be found and engulfed before 
they go into immunostimulatory secondary necrosis, and therefore need to advertise 
their death already in the early stages of apoptosis by sending out 'find-me signals'. 
These signals can be lipid lysophosphatidyl-choline, spingosine 1-phosphate (S1P), 
the fractalkines, and the nucleotides including ATP.(143, 144). To avoid recruitment 
of neutrophils, additional keep-out signals are released, for example lactoferrin(145). 
ATP is also released in very low concentration, as long as the cell membrane is intact 
(146). The uptake is important in maintenance of self-tolerance (147) and DC 
phagocytosing antigen-loaded apoptotic cells are seen to induce tolerance(148, 149) 
unless the DC is receiving an activation/maturation signal during uptake of the 
apoptotic cell (150, 151). 
 Once they find the dying cells, the apoptotic cells encourage the macrophages 
to phagocytosis, by expression of eat-me signals. The most classic one is the 
"flipping-out" of phosphatidylserine (PtdSer), which normally is present on the inner 
leaflet of the plasma membrane. Other eat-me signals include changes in charge and 
glycosylation patterns, alteration in intracellular adhesion molecule-1 epitopes on the 
cell surface and exposure or the ER-protein calreticulin.(147, 152, 153) 
 Since these signals are released early in apoptosis, they should be released 
while the cell membrane is still intact. The mechanisms may involve S1P kinases, 
binding to PtdSer while it is flipped out (154) and Pannexin-1 pore formation, 
induced by cleavage by caspase-3 and -7 (155). 
 Necrotic cells, caused by either by physical cell destruction or necroptosis, are 
highly inflammatory and can cause neutrophil influx and sterile inflammation through 
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the release of various DAMPs (156). Pyroptosis is also seen as an inflammatory form 
of death. However, unlike necrosis it is specifically caspase-1-dependent.  It also 
releases various DAMPs (134) but its inflammatory signatures are still under 
investigation. 
 
In summary, these different forms of cell death are well controlled and have the 
ability to regulate each other in sophisticated manners. The type(s), of cell death that 
occur in various cell types and how it is achieved is not always easy to predict. 
However, as a whole it is likely to be strongly influenced by the trigger(s), 
environment, and the time frame in which it occurs. 
 
1.3 THE ADAPTIVE IMMUNE SYSTEM 
 
Generally, the adaptive immune system does not play a role in defense until 
days/weeks after infection occurs. Since development of adaptive immunity also 
involves the development of memory lymphocytes, repeated exposure to a pathogen, 
alternatively a vaccination program, results in a faster and more prominent adaptive 
immune response. Generally, adaptive immunity can be divided into two parts: the 
cellular responses mediated by T cells, and the humoral responses mediated by B 
cells. T cells can be divided into numerous subsets including CD4+ T cells, CD8+ T 
cells and CD4+ regulatory T cells (Tregs). Standard CD4+ T cells generally function 
as T helper (Th) cells producing cytokines able to support B cell and CD8+ T cell 
development and differentiation. CD8+ T cells, with the help of CD4+ T cells, 
develop into cytotoxic T cells (Tc) with the ability to kill infected target cells.(1) 
 
Normally, adaptive immune responses are promoted by cells expressing PRRs. 
Antigen-presenting cells (APCs), namely macrophages, DC and B cells, recognize 
foreign particles, phagocytose and degrade it.  Phagocytosed particles are processed 
into peptides and presented on MHC class I or class II complexes to activate T cells in 
secondary lymphoid tissue. Exogenous antigens are presented by MHC class II 
molecules where they activate CD4+ T cells, whereas both exogenous and 
endogenous peptide antigens such as bacteria, viruses or tumor cells can end up in 
MHC class I molecules to activate CD8+ T cells. Normally peptides from general 
protein turnover is displayed in MHC class I, but in the case of intracellular pathogens 
or mutated proteins, these proteins will be exposed and activate CTLs previously 
activated primed and licensed by APCs. The activation of the CTLs triggers them to 
kill the antigen-presenting cell.(157) Presentation of exogenous antigens on MHC 
class I requires cross-presentation, which mainly is performed by specific DC subsets 
by mechanisms not fully understood (158, 159). Generally, it has been observed that 
antigens from intracellular bacteria residing inside phagosomes and presented on 
MHC class II while intracellular bacteria escaping the phagosomes into the cytosol 
are presented on MHC class I molecules in a method analogus to viral infection.(157) 
 
While APCs such as macrophages and DCs recognize pathogens by recognition of 
PAMPs and engulf antigens, the B cells express membrane-bound antibodies that can 
bind to and promote the engulfment of antigens. Endocytosed antigens are processed 
into peptides and presented on MHC class II molecules. When a CD4+ T cell detects 
presented antigen together with the proper co-stimulatory molecules, the CD4+ T cell 
produce cytokines that allow the B cell to differentiate into an antibody-secreting 
plasma cell. It also stimulates the B cell to class switch antibody isotype from the 
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standard IgM or IgD to IgG, IgA, or IgE as well as form memory populations. 
Antibodies secreted by plasma cells can neutralize and/or target microbes for 
degradation by numerous mechanisms.(1) 
 The CD8+ cytolytic T lymphocytes (CTLs) are the main cytolytic cell of the 
adaptive immune system. Upon recognition of antigens presented on MHC class I 
molecules by APCs, CD8+ T cells develop into antigen-specific memory CTL, 
effector CTL or both. This process is more efficient if supported by CD4+ T cells 
producing cytokines in responses to antigens also presented on class II MHC(160). 
Cytotoxic T effector cells can kill virus-infected cell, thereby controlling viral 
replication. The killing is either mediated by release of granules containing 
granzymes and perforin or by induction of apoptosis by Fas-Fas ligand interactions 
between the infected cells and the T cell. Additionally, the CTLs also produce 
cytokines such as INF-γ. INF-γ induces direct anti-microbial and anti-tumor 
mechanisms, recruits leucocytes, promotes maturation and differentiation of many 
cell types, enhances natural killer cell (NK) activity, regulates B cell function and 
antibody class switching (161). 
 
The type of effector function that dominate the adaptive immune response depends on 
the pathogen and is can be influenced by the types of cytokines secreted by various 
cells upon infection. Simplified, the control and expansion of Tc and B cells is 
controlled by CD4+ Th cell sub-types and the responses they make after detection of 
presented antigen (1). Type 1 Th (Th1) cells produce a cytokine profile, typically 
INF-γ and IL-2, which supports inflammatory-style responses and activates 
macrophages and cytolytic T cells, leading to a predominantly cellular immunity. It 
also induces antibody-mediated responses in certain subclasses of the IgG isotype - 
IgG2a. Type 2 Th (Th2) cells mainly activate B cells and antibody production through 
production of cytokines such as IL-4, IL-5, and IL-13. The response is associated with 
IgG1 and sometimes IgE antibody isotype. Generally, regulatory T cells (CD4+ 
Tregs) restrain and control the activity of responding lymphocytes to prevent 
autoimmunity and tissue damage. Th17 cells producing IL-17A, IL-17F, and IL-22 
can rapidly initiate immune responses dominated by neutrophils. The defense is 
essential in the defense against extracellular bacteria, fungi and opportunistic bacteria, 
especially in mucosal tissue, but also involved in viral defense. IL-17A stimulates 
epithelial cells and fibroblasts to produce inflammatory mediators, thus promoting 
granulopoiesis and neutrophil recruitment. Further the Th17 cytokines also induce 
production of cytokines and antimicrobial peptides from both immune and non-
immune cells such as mucosal and epithelial cells. IL-17 can also enhance the 
capacity of CD4+ T cells to produce IL-2, as well as enhance the proliferation of both 
conventional T cells and Treg cells. Th17 cells are associated with autoinflammatory 
diseases and gastric inflammations.(162, 163) 
 
1.4 VACCINES 
 
The goal of a vaccine is to educate the immune system to recognize a pathogen in the 
absence of infection and thereby create long-lasting immune-based protection against 
said pathogen. In 1796, Edward Jenner performed the first well-documented 
vaccinations. During a time when smallpox spread over the world, Jenner had 
observed that the women who where milking cows seemed to be protected against the 
disease. Jenner inoculated people with the smallpox related cowpox and could 
observe that they were less likely to get infected by the dangerous smallpox. Now 
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smallpox is in principle eradicated, and vaccines are known to be one of the most life-
saving inventions ever. 
 
Historically, vaccine efficacy has been based on empirical data, and there are still no 
detailed mechanisms understanding the correlates to efficacy. Often, the vaccine 
“take” is measured by induction of an antibody response and the titer induced is 
observed to be a correlate of protection (164). 
 There is a great need for research and insight into how vaccines work in order 
to design more efficient vaccines and more specific immune-boosting additives, so-
called adjuvants. In the work presented in this thesis we are trying to evaluate the 
adjuvant properties of flagellin and to decipher the mechanisms behind it.  
 
1.4.1 Traditional vaccines 
 
The majority of classic vaccines, such as smallpox, measles, mumps, rubella, polio 
(Sabin) and yellow fever, are live attenuated vaccine. In these formulations, the 
vaccine-microbe has lost its pathogenicity through several passages in cell cultures or 
has been grown in a way (cold passage) that promotes adaptation to a non-optimal 
environment. Alternatively, a closely related virus can be used instead of the primary 
pathogen, as in the example of smallpox vaccine. These vaccines cause a mild 
infection with less pathology that induces cross-protective adaptive immune memory 
against the major pathogen. This infection may however cause disease in rare cases 
and it is not advisable to be administrated to immunocompromised individuals.  
 A similar but safer strategy to vaccine development is to use inactivated non-
replicating vaccines. Common vaccines such as influenza virus, polio virus (Salk) and 
hepatitis A are inactivated virus vaccines. However these vaccines in their current 
forms have a tendency to skew the immune responses towards predominantly humoral 
responses. In many cases this is not necessarily a barrier to successful vaccine 
development. However, it may be that a mixed cellular-antibody response may 
provide even greater protection than a response dominated by one arm of adaptive 
immunity. The predominantly humoral responses elicited by current influenza virus 
vaccines are sufficient to confer seasonal influenza protection. However, the current 
vaccination strategies require yearly production of a new vaccine as the influenza 
vaccines fails to provide strong cross-protection against emerging viral strains. Hence, 
we need new flu vaccines for every season. Rapidly mutating viruses, such as 
influenza and HIV-1 can evade humoral immunity by antigenic drift and shift (165). 
The immune system preferable recognizes variable rather than constant parts of the 
virus. A current goal in flu vaccine research is therefore to make a universal influenza 
vaccine that is efficacious and one strategy is to targets constant parts of the virus that 
it cannot afford to mutate.  
 An alternative to whole virion vaccine is subunit vaccine, which is the use of 
specific viral proteins, usually surface proteins since these are primary targets for 
neutralizing antibodies. This strategy is currently used in vaccines against hepatitis B 
and human papilloma virus. However, also this strategy mainly elicits antibody 
response towards variable parts and furthermore subunit vaccines do not contain any 
natural PAMPs, in contrast to whole virions, and addition of adjuvants is therefore 
required. 
 Also even smaller parts of the virus can be employed. Peptides are short 
stretches of 8 to 30 amino acids and the ones used in vaccines represent epitopes 
known to induce strong immune responses. This possesses advantages such as easy 
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production and the possibility to rapidly alter the amino composition however, 
peptide vaccines are generally less immunogenic than whole proteins and require 
strong adjuvants.  
 
1.4.2 Genetic vaccines  
 
Genetic vaccines, either as plasmid DNA or recombinant viral vectors, are a 
promising alternative approach to traditional protein vaccines for the prevention and 
treatment of infectious diseases, cancer and allergy. These vaccines work by 
producing the antigen of interest within the cells of the recipient from the genetic 
construct. 
Viral vaccine delivery vectors such as Modified Vaccinia Virus Ankara 
(MVA), based on Vaccinia virus, and ALVAC, based on a Poxvirus, have been 
extensively passaged to attenuate the virus and are now considered to be safe enough 
to be used as vectors in human vaccines. However, one problem with the use of viral 
vectors to deliver antigen-producing genes is the risk for pre-existing anti-vector 
immunity. In this scenario, neutralization of the vaccine occurs before successful 
“infection” and production of protective antigen due to the recipient harboring 
neutralizing antibodies to the viral delivery system. Additionally, the use of viral 
vaccine delivery vectors may have limited utility because previous vaccinations with 
the same technology may promote neutralizing antibodies affecting efficient boosting 
or responses to new antigens. 
 
1.4.2.1 Plasmid DNA vaccines 
 
Non-living/replicating plasmid-based DNA vaccines are composed of a bacterial 
plasmid that encodes the antigen of interest under the control of a strong eukaryotic 
promoter. This approach provides a range of advantages over the conventional virus 
or protein based vaccines as it is a safe, rapid and cost effective, and does not suffer 
problems from improper folding of a protein antigen. The stability of DNA simplifies 
administration and it is also very flexible as the plasmid vaccine sequences can easily 
be changed to adapt to changes in the antigenic target. For example antigenic drift and 
shift of pandemic mutated influenza virus. 
 In the end of the 1980s and early 1990s it was discovered that naked DNA 
when injected intra-muscularly generated in vivo expression of the plasmid encoded 
reporter gene, and could be used as vaccine vectors. Short thereafter, experiments 
showed that genes encoding influenza virus could protect mice from subsequent 
influenza inflection.(166, 167) 
   
During DNA vaccination, the plasmid encoding the antigen is delivered to the skin, 
muscle or mucosal tissue through one of several delivery methods. Using a poorly 
identified host cellular machinery, the plasmid enters the nucleus of transfected local 
cells including myocytes, keratinocytes and/or APCs. Once in the nucleus, the 
plasmid-encoded genes are expressed and transcribed into antigen proteins, which are 
seen by the immune system as foreign. Directly transfected somatic cells can secrete 
the synthesized protein to resident APCs or degrade it and display it on MHC class I. 
Resident APCs can present the endogenous peptide on MHC class I either after direct 
transfection or cross-presentation after uptake of dying transfected cells (158). 
Additionally, APCs can present the peptides on MHC class II after uptake of secreted 
protein antigens. The activated antigen-loaded APCs migrate to the draining lymph 
18	  
nodes where they present the antigenic peptide-MHC complexes to naive T cells. This 
step promotes the activation and expansion of T cells and/or activation of B cells and 
antibody production. In this way, both humoral and cellular immune responses are 
generated in response to a plasmid DNA vaccine.(Figure 2) Furthermore, such an 
approach is not hampered by the anti-vector immunity observed for the attenuated 
viruses or bacterial vaccine vectors (168). 
 
An early safety concern of DNA vaccines was the risk of integration (partial or 
complete) of the plasmid DNA into the host genome. Fortunately, this has been 
shown not to be the case and indeed, the rate of plasmid integration is negligible and 
much lower than the spontaneous mutation rate of DNA (169). Another safety 
concern was the risk of producing anti-DNA or anti-nuclear antibodies in response to 
the vaccine resulting in autoimmunity. However, to date there are numerous studies 
indicating that there is no evidence of autoimmunity associated with DNA-
vaccination (170-174).  
In animal studies, plasmid DNA vaccines have been shown to provoke protective 
immunity to infections including HIV, malaria and influenza (175). In 2005 the first 
DNA vaccine for veterinary use obtained licensure. The vaccine was for prevention of 
disease caused by infectious hematopoietic necrosis virus in farm raised Atlantic 
salmon and it has been followed by prevention of West Nile virus in horse and also 
therapeutic DNA vaccine to treat melanoma in dogs. 
 In spite of these breakthroughs in animal studies, in human the non-
living/replicating DNA vaccines have suboptimal immunogenicity when compared 
with traditional protein-based vaccines. So far, no plasmid DNA-vaccines have been 
able to elicit protective immunity in humans. It is due to these reasons that many 
researchers are actively pursuing techniques and technologies to improve the 
immunogenicity of non-living/non-replicating DNA vaccines. 
 
1.4.2.1.1 Features of the vaccine plasmid 
 
To function as an expression vector and DNA vaccine, the plasmid is required to 
contain certain basic elements described here. Additionally, through optimization of 
the plasmid backbone the uptake and expression of plasmid-encoded protein can 
enhance the built-in adjuvant function of the plasmid itself and a list of examples is 
provided below; 
1. Basic elements: An origin of replication that allows for replication of the plasmid in 
bacteria and affordable production of the vaccine.  
2. Antibiotic resistance gene: for selective growth in bacteria. Can be removed for 
safety concerns if necessary. 
3. A promoter to initiate transcription of the encoded protein. This requires a strong 
eukaryotic promoter since microbial promoters not necessarily are optimized to drive 
mammalian gene expression. This promoter is designed not be silenced despite 
expression in different cell types. 
4. A polyadenylation (poly-A) signal in the 3' end of the gene. This is required for 
proper termination of transcription and stabilizing the mRNA during the export from 
the nucleus. 
5. Additional modifications including a translational enhancing sequence called a 
Kozak sequence upstream of the antigen genes start site. 
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Figure 2: Immune response after plasma DNA vaccination. Adapted from Kutzler 
2008. 
 
1.4.2.1.2 Increasing the immunogenicity of plasmid DNA vaccines  
 
The cellular uptake of injected DNA plasmid is inefficient. Transfection of cells in 
culture often results in high levels of produced protein. However, delivery of plasmid 
DNA to cells as part of a larger system such as the body is complicated. The ideal 
gene delivery system should protect the DNA from degradation by extracellular 
enzymes, e.g. endonucleases, and protect DNA from the presence of serum and 
interstitial fluids, as well as deliver the DNA mainly to the target cell of interest. Once 
inside the cell, ideal delivery technology should also prevent the DNA from getting 
degraded in endosome-lysosome compartments if it should happen to enter a cell by 
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endocytic mechanisms. Additionally, the correct/appropriate adjuvant signals have to 
be provided in order to dictate the type of immune response to be induced. 
 There are many different strategies that can be used to enhance the 
immunogenicity of DNA vaccines. These can be techniques to optimize the cellular 
uptake of plasmids by various delivery methods. Special plasmids allow co-
expression of antigen and adjuvant in the same plasmid. Certain technologies make 
use of different viral vectors and antigenic gene codon optimization to maximize the 
antigen expression. Prime-boost schedules may be optimized for the type of vaccine 
recipient as well as the use of different adjuvant technologies. 
To induce an efficient immune response, not only the strength of the response but also 
its quality is of importance. The most standard way to evaluate T cell responses is the 
magnitude, commonly represented by the frequency of antigen-specific T cells 
producing a specific cytokine, such as IFN-γ. However, this only reflects one 
parameter of the T cell function and does not always correlate with protection. The T 
cells function is not only cytokine production but also includes the ability to 
proliferate or secrete growth factors, secrete chemoattractants to organize the immune 
response, and, for the CD8+ T cells, perform direct killing through cytolytic 
mechanism or secretion of cytokines. The optimal combination of delivery method 
and adjuvant needs to provoke these multifunctional immune responses. 
 
1.4.2.1.2.1 Adjuvants  
  
The inclusion of adjuvants in a vaccine can improve both the strength and quality of 
the response by providing a depot effect, protect the vaccine from degradation, 
facilitate uptake by APCs and modulate the immune response to tilt it to a more 
favorable Th1/Th2 ratio. They also have the ability to improve the immune responses 
in poorly responding individuals and reduce the amount of antigen.  
 Over the past two decades, our increased understanding of innate immunity 
and antigen presenting cells allows us to rationally design adjuvants. Indeed, bacterial 
cell walls, bacterial DNA and viral RNA, present in vaccines for nearly a century are 
now known to engage distinct TLRs and activate TLR expressing antigen-presenting 
cells. 
 Many of the traditional adjuvants are still among the most widely used, and 
tested also in conjunction with DNA vaccines. These include oil-in-water emulsions, 
bacterial components and aluminum salt (Alum) (176). Aluminum salts, commonly 
referred to as alum, are currently the most used adjuvants in human vaccines. They 
result in a gel-like matrix that creates a depot of antigen, and additionally it activates 
the NLRP3 inflammasome (177). Oil–water emulsions also work by sequestering the 
antigen and slowly releasing it. The most classic water-in-oil emulsion, incomplete 
Freund's adjuvant, is widely used together with livestock vaccines, but not in human 
because of its tendency to induce granulomas at the injection site (176). However, 
MF59, a variant of the biodegradable oil squalene is suitable in human (178). Other 
adjuvant approaches in clinical trials are PRR agonists such as flagellin, MPLA (an 
non-toxic LPS-derivate) and Imiquimod (TLR-7 ligand), as well as cytokines such as 
IL-12, IL-2, IL-15 and GM-CSF (176). Also chemical adjuvans including liposomes, 
polymers and microparticles have been shown to enhance the immunogenicity of 
DNA vaccines, mainly by facilitating delivery and uptake of DNA (179). 
 
The DNA vaccination plasmid itself has adjuvant properties and may function in 
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numerous ways. Cysteine poly-Guanosine (CpG) motifs in the backbone can be 
recognized by TLR9 and trigger proinflammatory response through MyD88 (180-
182) The double-stranded DNA of the plasmid can activate cytoplasmic DNA sensors 
and signaling pathways such as TBK-1 and STING, thereby inducing type 1 
interferons (183-186). RIG-I (187) and Aim2 (187, 188) have also been shown to 
sense cytosolic DNA and could plausibly be involved in sensing a DNA vaccine. 
 
1.4.2.1.2.2 Delivery methods 
 
The gene-gun technique was the first delivery device used to increase the transfection 
rate during DNA vaccination. With this technique, the plasmid is coated on gold 
particles and shot directly into the outer living layers of the skin. In this way the DNA 
is delivered directly into the cell cytoplasm or nucleus instead of into the extra-
cellular space as with injections, which drastically increases plasmid uptake and 
require much smaller amounts of plasmid to elicit immune responses compared to 
needle injections. It induces cellular and humoral immunity in mouse and humans 
(189-192) but as it skews the response towards Th2 (193, 194) its use is sometimes 
limited. 
 
Electroporation is currently the most favored and potent technology for delivery of 
naked DNA vaccines. The DNA is injected intra-dermally or intra-muscularly 
followed by a brief electrical stimulation at opposite sides of the injection site. This 
technology is thought to permeabilize cell membranes near the DNA injection site 
and improve plasmid delivery to surrounding cells (195). This, in turn, leads to 
greater antigen production. Additionally, it causes a mild inflammation inducing 
proinflammatory cytokines and migration of immune cells (196, 197). It was first 
used for cancer immunotherapy but is now known to enhance DNA vaccine efficacy 
and induce robust immune responses comparable to those with protein vaccines with 
the added advantage that it efficiently promotes Tc responses (198). This technology 
has been shown to increase the immunogenicity of numerous vaccines antigens as 
well as enhancing vaccine responses in larger animals that previously have 
demonstrated poor responses to plasmid DNA vaccination (199). EP can be applied 
both intradermal and intramuscular depending on the length of the needles and 
electrodes used.  
 Electroporation vaccination is currently in several clinical trials against both 
infectious diseases and cancer (clinicaltrials.gov) and is utilized for the administration 
of a DNA-encoded growth hormone veterinary product for pigs. The main downside 
for electroporation is the brief discomfort, which may prohibit it from being used in 
prophylactic vaccines.  
Mucosal surfaces have major advantages as immunization sites since they are easily 
accessible, rich in immune cells and the site of entry for many pathogens. Mucosal 
delivery is also associated with the ability to elicit higher mucosal immune responses, 
including IgA antibodies(200).However, most antigens are poorly immunogenic when 
administrated at mucosal surfaces and require appropriate delivery systems and 
adjuvants in order to induce potent immune responses. Numerous delivery systems 
and adjuvants have been evaluated for mucosal administration, including liposomes, 
immunostimulatory complexes, CpG oligodeoxynucleotides, bacterial toxins, 
nanoparticles and microparticles (200). Most studies focus on intranasal or oral 
administration as these are clinically easy to access. There are currently licensed 
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mucosal vaccines based on killed or live-attenuated microorganisms. These include 
oral vaccines against poliovirus, rotavirus, S. typhimurium and V. cholerae and the 
intranasal influenza vaccine FluMist (201). The live seasonal flu vaccine FluMist 
contains live-attenuated intranasal influenza vaccine from three live influenza viruses 
and has been approved since 2003. It is administered as a nasal spray, and it has 
proven to be well tolerated and efficient. The virus is cold-adapted and can only 
reside in cooler parts of the nose and not infect the lungs (202, 203).     
 
There are a variety of additional delivery methods being evaluated including the non-
invasive devices where the DNA is propelled into the skin or muscle, and invasive 
using conventional tattoo machines. All methods have their pros and cons and 
optimization of the delivery method can clearly enhance the efficacy of DNA 
vaccines. 
 
1.4.2.1.2.3 Heterologous immunization 
 
Vaccination strategies based on a combination of more than one vaccine modality has 
been shown to enhance and broaden responses against pathogens such as HIV or 
malaria, and most of the current clinical HIV studies utilize this strategy 
(clinicaltrials.gov). These strategies typically involve a priming using plasmid DNA, 
followed by a boost with a similar but not identical antigen in a viral vector. The 
advantages are that the prime induces a highly specific priming but weak response 
which is boosted by the viral vector, allowing for an efficient expansion of the 
antigen-specific immune response. Additionally, this strategy circumvents the risk for 
vector-specific immune responses that can lower the effect of repeated 
immunizations. 
 Another alternative is priming with plasmid/viral vector DNA and boost with 
protein. This is a highly promising strategy as it combines the best of two worlds by 
providing the possibility to prime a strong T cell response using the DNA vaccine 
then maximizing the antibody responses with the protein boost.(204, 205) 
Additionally, this method does not use an attenuated pathogen or infectious delivery 
system which would broaden its use in immunocompromised individuals. 
1.4.3 Safety issues of vaccines and adjuvants 
 
The safety standard of prophylactic vaccines and adjuvants need to be extremely high 
as they are products intended for healthy individuals. The safety of routinely used 
vaccines has over the past several decades been examined in both randomized-
controlled trials and observational studies with great safety records. However, it 
would be incorrect to paint vaccines as being totally safe. With the great genetic 
variance among humans, there may always be individuals with unpredictable 
reactions. The risks with vaccinations must be put in perspective to risks of possible 
adverse effects of the vaccine with severity of the health effects associated with the 
diseases. The risk populations, such as young children, elderly and people with 
chronic diseases, must be taken into consideration. Their impaired immune system 
both put them at higher risk for infection and decreases the vaccination efficacy. The 
inability of these populations to receive vaccines highlights the importance of 
vaccines to promote herd immunity. In the western world the children vaccination 
program have more or less eradicated many diseases, and is it easy to forget how 
deadly several vaccine-preventable childhood diseases can be and instead question the 
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need and safety of vaccines. This has further increased the public demand for 
evidence of vaccine safety. 
 Addition of adjuvants triggers the immune system and may make the response 
harder to predict and in the worst cases too strong. However, adjuvants are often 
necessary for the efficacy of the vaccine, especially in elderly people. Addition of 
adjuvants can also make the vaccine much more cost effective. For safety it’s 
important to thoroughly test the new vaccine formulas in phase III studies and also 
established have post-marketing surveillance program and follow up reports of 
possible adverse effects. 
 
Most adverse effects after vaccinations are common local reactions including pain, 
swelling, and redness at the injection site. Systemic reactions, including fever, 
irritability, drowsiness, and rash, may also occur. Allergies to any of the components 
used in vaccine development, such as gelatin, egg or traces of neomycin, should be 
taken into consideration. 
 
Many diseases have been suggested to occur in correlation with vaccine use without 
significant scientific evidence. Since the onset of diseases, miscarriage etc. can 
coincide with vaccination without causality, it is important to have information of 
background levels of different conditions. Sadly, the idea that the triple-vaccine for 
measles, mumps and rubella would cause autism is still widely spread after the 
falsified study by Andrew Wakefield in 1998, which was withdrawn from Lancet 
when scientific data manipulations were revealed (206, 207). Vaccinations are also 
not associated with an increased risk of Crohn’s disease, as previously suggested 
(208). 
 Severe adverse effects such as increased risk for certain diseases have 
occasionally been correlated to vaccination, such as encephalitis after measles 
vaccination (209), febrile seizures in young children after the seasonal influenza 
vaccine Fluvax (210), asthma after immunization with live attenuated influenza 
vaccines (211, 212). The risk for the neurological diseases GBS was significant 
increased during the swine influenza immunization program in USA 1976 (213) but 
this has not been observed since (214). Another drawback for vaccinology was the 
STEP trial, a HIV-vaccine study enrolling 300 individuals at high risk of HIV-
infection, which was discontinued due to futility (215, 216). The vaccine based on the 
Adenovirus type 5 (Ad5) vector, increased the incidence of HIV-infection rather than 
protected, and pre-existing Ad5 immunity was subsequently shown to increase the 
risk of acquiring HIV (215). 
 The worst case of vaccine related events lately is the association between 
narcolepsy and H1N1 vaccine. In 2009, the pandemic influenza A (H1N1) virus 
spread rapidly, resulting in millions of cases and over 18,000 deaths in over 200 
countries (217). Vaccines ware licensed using fast track procedures and many 
countries decided to mass-vaccinate the population, on the recommendation of the 
world health orgination (WHO). The USA, Australia and parts of Europe offered only 
non-adjuvanted vaccines. In the rest of Europe, the offered vaccines were mainly two 
versions with adjuvants based on the oil-in water adjuvant squalene: Foceteria 
(Novartis) with MF59 and Pandemrix (GlaxoSmithKline) with AS03. AS03 is 
squalene in combination with α-tocopherol (a form of vitamin E) (217). The 
Pandemrix vaccine has been associated with cases of narcolepsy. Sweden, Finland, 
Norway, Ireland and England have reported that Pandremix induced a 3- to 14-fold 
increased risk for children and adolescents below the age of 20 (217-222). Narcolepsy 
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is a rare conditions; for Sweden this entailed an increase from 0.97 to 4.06 cases per 
100,000 inhabitants (221). 
Narcolepsy is a chronic neurological disorder of excessive daytime sleepiness, often 
accompanied by cataplexy; sudden muscle weakness triggered by strong emotion. It is 
tightly associated with the human leukocyte antigen (HLA)-DQB1*0602 haplotype 
and the loss of the neurons normally producing hypocretin, a neurotransmitter 
important for regulation of sleep and wakefulness, possibly by autoimmune reactions. 
These associations also hold true also for the vaccine-associated cases. How the 
vaccination triggered the onset of disease is unknown but narcolepsy has also been 
correlated to upper airway infections such as Streptococcus pyogenes (223). In China 
the occurrence of narcolepsy is seasonal and correlates with upper airway infections 
including influenza. The number of narcolepsy cases increased 3 fold during the 
winter 2009-2010 to return to baseline levels two years late. Since only 5.6 % of the 
patients were vaccinated (224, 225), the trigger is suggested to be the infection itself, 
and that the vaccine and the infection may trigger the same reaction.  
 In retrospect one can say that the decision to mass vaccinate and include 
children, however the severity if the influenza was hard to predict. The induction of 
narcolepsy was an unpredicted adverse effect, and too rare to catch in clinical studies. 
What should be discussed is whether it was correct to continue with the vaccination 
program when the cases of narcolepsy were reported, and what to learn for the next 
pandemic. These incidents are not only disastrous for the affected children, but also 
for the attitude to vaccines as well as the trust in scientists with subsequent decrease 
of vaccine coverage. 
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2 AIMS 
 
 
1) To perform DNA vaccinations and compare immunization by skin 
electroporation to intramuscular injection with special focus on 
multifunctional CD4+ T cell responses (paper I). 
 
2) To evaluate the adjuvant properties of plasmid encoded secreted flagellin 
when delivered by different routes representing mucosal, systemic, and dermal 
tissue compartments (paper II). 
 
3) To study responses to unprimed NLRC4 inflammasome activation and 
inflammatory properties of pyroptosis (paper III). 
 
4) To study the effect of various priming pathways and additional stimuli on 
NLRC4 inflammasome activity (paper III). 
 
5) To see if metabolic changes activated by TLR agonism correlated with post-
translational modifications of HMGB1 released during pyroptosis (paper III).  
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3 METODOLOGY 
 
Presented below is a brief overview and discussion about some of the methods used in 
the studies included in this thesis. For more comprehensive descriptions, please see 
respective paper. 
 
Immunizations (paper I and II) 
Electroporation: The mice were gently anesthetized using Isofluran. The flanks were 
shaved and the vaccine mixture (10µl) injected intra-cutaneously in both flanks 
forming a small bubble of fluid. Immediately after injection a needle array electrode 
was placed over the injection site and a brief pulse of low voltage currant is applied to 
over the area. 
Intradermal injection: The injection procedure was the same as describe for above 
without the electroporation step. 
Intramuscular injection: The mice were restrained and the vaccine mixture injected 
into the quadriceps. Total amount of antigen was 10ug/mouse of pOVA and 10 
ug/mouse HIV-1 in a 50µl volume. 
Intranasal immunization: The mice were gently anesthetized using Isofluran and laid 
with the dorsal side up. The vaccine mixture was dropped is each nostril with the 
mice breathing it in. The mice were supported until they regained consciousness. 
Total amount of pOVA was 5ug/mouse in a 10µl volume. 
Gene gun immunization: The mice were anesthetized using Isofluran. The abdominal 
skin is shaved and the g.g. is held directly against the abdomen and discharged.  0.5 
mg of gold particles was coated with 0.5ug pOVA/mouse.  
 
The immunization schedules are indicated in paper I and paper II. 
 
Immunization antigens (paper I and II)  
The antigens used in the vaccine studies in this thesis are plasmid DNA encoding 
Ovalbumin (pOVA) (paper II) and the HIV-1 antigens pGag (the whole 55kDa 
antigen) (paper I), pGag24 (a smaller 24kDa region) (paper II), and pgp160 (full-
length gp160) (paper II).  
pOVA encodes an egg white protein commonly used as a model antigen in mice due 
to its robust immunogenicity and known class I and II MHC peptide epitopes. pGag 
encodes a human codon optimized HIV clade C Gag (p55). pGag24 and pgp160 
encode codon optimized HIV clade B p24Gag and gp160, respectively. All antigens 
reside in the Invitrogen expression plasmid pcDNA3.1/Zeo. As an empty vector 
control the same plasmid is used. The pcDNA3.1/Zeo plasmid has a cytomegalovirus 
(CMV) enhancer-promoter, commonly used for DNA vaccines because its abilty to 
drive high constitutive expression levels of transcripts in most cells.  
 
Studies of functional immunity (paper I and II) 
The immunity elicited by immunization was evaluated using the methods multicolor 
flow cytometry, ELISA, and ELISPOT. ELISA and ELISPOT are sensitive and 
reliable methods. Flow cytometry provides the ability to distinguish cell types and 
detect multiple cytokines from single cells in mixed populations. The FLUOROspot 
technique (not used here) also has the ability to detect two cytokines produced by the 
same cell. However, this is still only two cytokines and without the ability to directly 
observe the cell type producing it.  
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Plasmid preparations (paper I-III) 
All plasmid preparations were made using Qiagen EndoFree Plasmid Maxi Kit.  
 
Western blot analysis (paper II-III) 
Western blot analysis (also called immunoblot) was used to confirm that the plasmid 
FliC versions were transcribed into proteins of the predicted size. It was also used to 
confirm processing of pro-IL-1β to IL-1β (17 kDa) and release of HMGB1. 
 
Establishing the retroviral inducible system (paper III) 
We have established a tetracycline-on based system to achieve inducible expression 
of C34-EGFP and C19-EGFP gene products in a mouse macrophage cell line. The 
gene induction is activated using a tetracycline analogue called doxacycline (Dox) 
and is indirectly determined by detection of EGFP expression in living cells by flow 
cytometry. The establishment of this system is further explained in 4.3 and paper III.  
 
The cell line B10R (paper III) 
Since we wanted to stably transduce cells and have the possibility to genetically 
modify them in additional downstream experiments, the use of cell lines were more 
appropriate than use of primary cells. Primary cells can be more relevant to 
physiological function, however there are functional differences between mouse 
strains and housing conditions that may account for different priming of immune cells 
derived ex vivo. Furthermore, primary cells are less well characterized, have limited 
life-span, will differ from time to time and will change over time in culture with the 
number of passages. However, cell lines are also affected by passaging and variations 
in culture conditions such as growth density. Indeed, we have noticed that our C34s 
drift in their ability to respond to expressed C34-EGFP over time. To avoid this, we 
limit the time the cells are cultured and thaw out fresh cells if they start to drift. 
Additionally the C34s have been single cell clone selected repeatedly. Most of the 
studies are done with 400,000 cells/700ul medium/well on a 24-well plate, as this is a 
cell density that allows for the harvesting of concentrated supernatants without culture 
overgrowth and decreases in cell viability during 24 hours. We have observed no 
apparent differences in pyroptosis when altering the cellular density before seeding or 
during Dox induction. Additionally the C34s have been single cell clone selected 
repeatedly with similar behavioral phenotypes (pyroptosis) observed. 
The cell line used in paper III is B10R, also known as Bcgr. This is a murine 
macrophage cell line established to study susceptibility to Mycobacterial infection. 
Bcg is a single, autosomal dominant gene that controls susceptibility or resistance 
species of Mycobacteria including Mycobacterium bovis (BCG), but also S. 
typhimurium and Leishmania donovani. There are numerous functional differences 
associated with the Bcg locus, however the candidate gene associated with resistance 
has been identified to be the gene natural resistance associated macrophage protein 
(Nramp1) encoding an endsomal resident protein. The resistance can be abrogated by 
a single amino acid substitution.(226, 227) The pleiotropic effects of Nramp1 are not 
fully understood but proposed to involve increased bactericidal activity, respiratory 
burst activity, responses to IFN-γ, NO production, iron transport and antigen-
presenting ability (226, 227). The human homologue NRAMP1 appears to have the 
same function and mutations in human NRAMP1 is associated with genetically 
predisposition to diseases including tuberculosis (228). 
 There is no such thing as the perfect cell line or mouse strain since and they all 
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have some differences. Inbred mouse strains have either the resistant (Bcgr) or the 
susceptible (Bcgs) allele and the common laboratory mouse strains C57BL/6 and 
BALB/c both have the Bcgs allele(94). Knockout mouse lines are most frequently 
constructed using 129-derived embryonic stem (ES) cells, which also have a Bcgr 
(226). The commonly used macrophage-like cell line RAW264.7 on the other hand 
lacks functional Nramp1 (229). 
 
Congenic B10A.Bcgr mice have been constructed by transferring the Bcgr allele of 
the A/J strain into the C57BL/10.A background using Nx backcross system. From 
these mice, bone-marrow derived macrophages have been immortalized by infection 
with J2 virus.(230) We choose to work with this cell line since it is derived from 
bone-marrow known to express all the necessary components for inflammasome 
activity. Furthermore, the C57BL/6 mice that B10R is based on is the most commonly 
used mouse strain for inflammasome studies. In contrast, the widely used RAW 264.7 
cells derive from BALB/c mice. We have phenotyped the cells by screening for 
surface markers using flow cytometry (S1, paper III) and gene expression using RT-
qPCR (Figure 1B, paper III). From the markers and genes we have studied, these 
cells appear to be typical macrophages. 
 
Monitoring TLR5 activation (paper II) 
293T cells were transfected with pFliC(-gly), pFliC(-gly)D34 or empty vector. The 
supernatants were confirmed to contain FliC proteins of the predicted size and used to 
stimulate mouse alveolar macrophages from TLR5-/- or C57BL6 mice, with 
recombinant flagellin and LPS used as positive control. Macrophage responses were 
evaluated by measuring release of TNFa by ELISA. The alveolar macrophages were 
obtained from bronchioaveolar lavage (BAL) washes harvested by flushing lungs of 
sacrificed mice with PBS. Alveolar macrophages were used because mouse, unlike 
human, bone-marrow derived macrophages do not express TLR5 (231, 232). 
 
Retroviral lethality screen (paper II) 
The retroviral lethality screen was based on a developed by Miao et al.(87). pFliC(-
gly), pcFliC(-gly), pFliC(-gly)Δ34, or pcFliC(-gly)Δ34 ORFs were inserted into the 
packaging vector pMSCV-IRES-GFP/neo and retrovirally packaged using Phoenix 
amphotropic cells. The supernatants containing viral particles were concentrated by 
centrifugation and transduced to B10R and 293T cells using spinduction. Three days 
after transduction the B10R cells were analyzed for viability and GFP expression. The 
ability for a certain flagellin version to induce pyroptosis in B10R cells were defined 
an absence of GFP signal relative to control constructs and GFP signals seen in 293T 
cells (non-responders). 
 
Monitoring cell death (paper III) 
Thus, the Nomenclature Committee on Cell Death (NCCD) has proposed that a cell 
should be regarded as ‘dead’ when 1) the cell has lost the integrity of its plasma 
membrane and/ or 2) the cell, including its nucleus, has undergone complete 
disintegration, and/or 3) its corpse has been engulfed by a neighboring cell in 
vivo.(113) Our methods to monitor cell death has focused on the first criteria. The 
assay used throughout paper III monitoring up-take of the membrane-impermeant 
fluorochrome propidium iodide (PI) by flow cytometry. The exception is the TMRE 
mitochondrial membrane potential assay where PI could not be used because of 
conflicts in the use of filter settings by the Fortessa. In this instance viability was 
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detected using the amine-reactive Viability Dye eFluor 450. In the PI assay, PI is 
passivly able to cross membranes and binds DNA in cells that have lost their plasma 
membrane integrity. This is a fast, easy assay with relatively low toxicity to living 
cells. Since pyroptosis is associated with the formation of a hypothetical plasma 
membrane “pore” during early stage of pyroptosis that could account for slight up-
take of PI, we have confirmed death by additional assays. We have also studied 
release of lactate dehydrogenase (LDH) a cytoplasmic protein that is released from 
cells during plasma membrane breakdown. Additionally, the dead cells have a 
forward-side shatter localization that is dramatically different from living cells. We 
find that the results using these different methods correlate with each other. As such, 
we are quite certain that the cells defined in our experiments as dead are indeed dead.  
 To initiate the production of pro-IL-1ß substrate for NLRC4 activity we prime 
the cells with LPS (100 ng/ml) and add Doxacyclin (500 ng/ml) to express the 
NLRC4 agonist. Apoptotic cell death in our assays is initiated by the standard 
apoptosis inducer etoposide (50 µM). In additional studies, NLRP3 activation has 
been induced by LPS priming and treatment with ATP (500 µM) alt. Nigericin 
(40mM).  
 
Monitoring responses to NLRC4 activation (paper III) 
There is no gold standard of how to estimate inflammasome activation. We are using 
pyroptosis, confirmed to be caspase-1 dependent, as our read-out. Other groups 
measure death, release of IL-1β or study cleavage of IL-1β or caspase-1. We control 
for caspase-1 activation is indirectly by detection of cleaved IL-1β. Release of IL-1β 
was detected by ELISA and cleavage by western blot.  
 
Protein over-expression (paper III) 
Protein over-expression is conducted by retroviral transduction of the cells with 
plasmids encoding for CrmA, cFLIP-L, cFLIP-S and Bcl-xL. The functional assays 
were performed as soon as possible post transduction and selection (around one week) 
to avoid drifting of the cells. We feel that genetically-encoded inhibitors are beneficial 
over chemical inhibitors as chemicals often have poorly characterized off-targets 
effects. 
 
Assays to evaluate mitochondrial functionality (paper III) 
Whole cell intracellular ROS was detected using CellROX Deep Red (Invitrogen Life 
Technologies). In this assay, the cells are stained with fluorogenic probes that are 
non-fluorescent in reduced form but when oxidized (by various forms of ROS) it 
exhibit strong fluorogenic signal that can be detected by flow cytometry.  
 
To determine changes in mitochondrial membrane potential, the cells were loaded 
with TMRE for 30 min, to washed and resuspended add it in a lower maintenance 
concentration of TMRE. The cells were activated with Dox +/- CsA or the positive 
control CCCP to activate a collapse of the potential. When applicable, CsA was added 
to cultures 1 h prior to TMRE loading. Decreases in membrane potential were defined 
by decreases in TMRE staining detected by flow cytometry relative to loaded, 
washed, and incubated but unstimulated cells. Since TMRE and PI overlap in 
fluoresent emission, Viability Dye eFluor 450 was used as an alternative to assess cell 
viability after activation. 
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Confocal microscopy (paper III) 
The plasma membrane (PM) of C34 and C19 cells were labeled with Cell Mask 
Orange and the cells imaged every 10 min for 22.9 h. The PM labeling, C19 and C34 
signals were detected and separated by spectral unmixing. 
 
Quantitative RT-PCR (paper III) 
Confirmation of gene expression in B10R/C34/C19 cells was done using RT-qPCR 
with SYBR Green primers. The expression was normalized with the house-keeping 
genes HPRT1 and GAPDH as endogenous controls and up- or down-regulation of 
genes calculated using the ΔΔCt method. The ΔΔCt method is an approximate 
method and only valid if the amplification efficiencies of the target and the 
endogenous control are approximately equal. However, all used primers have been 
titered to confirm that their efficacy is similar to the controls. To confirm size of the 
predicted amplification products they were visualized on agarose gels stained with 
Gel Green Nucleic Acid Stain. In additional studies, RT-qPCR was also used to detect 
the presence of mtDNA.  
 
LC-MS/MS (paper III) 
Liquid-chromatography mass spectrometry (LC-MS/MS) was used to define the 
redox and acetylation state of HMGB1. HMGB1 was immunoprecipitated from pre-
cleaned supernatants using a polyclonal antibody. Free thiol groups were alkylated 
with iodoacetamide. The cysteins residues in disulphide bonds were then reduced 
with dithiothreitol (DTT) and the newly exposed thiol groups were labeled with 
NEM. The samples were digested with trypsin or GluC, desalted and individual 
HMGB1 peptides were characterized using an AB Sciex TripleTOF 5600. 
 
Statistics 
Data were analyzed using Graphpad Prism v5.0d software and is shown as mean +/- 
standard error of the mean (s.e.m.). For statistical analysis two-tailed Student t-test 
was used and p ≤ 0.05 was considered significant. 
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4 RESULTS AND DISCUSSION 
 
4.1 Increased immunogenicity using intradermal electroporation 
 
Even though HIV-1 was discovered 30 years ago (233), there is still no efficient HIV-
1 vaccine. The vaccine field currently put more weight on mechanistic understanding 
and less on empirical observations than it used to, still, there is not yet clearly defined 
immune correlate of protection for diseases such as HIV-1. To understand the 
correlations is complicated, as the natural immune response to HIV-1 in general is 
unable to clear the infection. There are however exceptions with individuals that 
remain persistently uninfected with HIV-1 despite frequent exposure. One such 
example is the well-studied cohort of sex workers in Nairobi, whose protection were 
associated with strong HIV-specific CD8+ T cells (234). Another exception are the so-
called elite controllers, who are infected with HIV-1 but capable to suppress the virus 
to undetectable viral load (235). There is not a simple explanation to how these 
individuals manage to control HIV-1 infection, however Gag-specific CD8+ T cells 
are implied to be important Characteristic of the controllers is not only the quantity of 
CD8+ T cells but also their polyfunctional capacity, or their ability to produce high 
levels of multiple cytokines and chemokines simultaneously (236, 237). However, 
this immune profile may correlate to control of infection rather than to protection. To 
generate hypotheses about the immune responses necessary for protection against 
HIV-1 infection, successful immunizations or studies in monkeys are needed. 
Additionally, clues can be obtained from other vaccines. 
 
Antibody titers are commonly considered to correlate with protection of vaccines. 
However, eliciting neutralizing antibodies to HIV-1 has been proven difficult with 
complicating features such as the rapid mutation rate of the virus and its heavy 
glycosylation.  In the individuals developing neutralizing antibodies, these arise first 
weeks after infection and tend to be strain-specific (238, 239).  Even though around 
30% of the infected individuals can produce broadly neutralizing antibodies, only 1%, 
the so-called elite-neutralizers develop extremely broad neutralizing antibodies 
capable of neutralizing 95 % of circulating HIV-1 strains (240-242). Moreover, 
passive transfer of broadly neutralizing antibodies to macaques has shown that these 
antibodies can protect against infection. There are still many unanswered questions on 
how to design antigens and optimize immunization schedules in order to be able to 
induce such broad and robust neutralizing antibodies by vaccination.(243, 244) 
 
Protection against HIV-1 probably requires a combination of humoral and multi-
functional cellular immunity as well as innate responses. Moreover, this will require 
durable T cell responses of sufficient magnitude and quality. In addition, the CD4+ T 
cells engaged in the response should not be provided as targets for HIV-1 infection 
and thereby fuel an infection. Great effort has been put into the development of CD8+ 
T cell inducing vaccines. These responses have been beneficial in macaque studies 
but their importance was questioned with the failure of the STEP trial (215, 216). 
However, the large, more recent RV144 trial conducted in Thailand, showed more 
encouraging results as it was the first HIV vaccine candidate to show significant, 
although moderate (31,2%, p=0.04), protection against infection (245). The vaccine 
was a combination of two vaccines, prime with multiple-antigen viral-vector 
(ALVAC-HIV) and boost with recombinant gp120 protein (AIDSVAX), both 
previously evaluated as safe but insufficiently protective on their own(246). 
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Numerous immunologic assays on samples from the study have been performed and 
are still being followed up. The vaccine induced antibodies directed to the V2 loop of 
gp120, which may block from binding CD4+ T cells (247). 
 
The use of optimized delivery devices can enhance immunization potency and 
preferably also the quality of the response. In paper I, we studied immune responses 
induced by immunization of mice with the plasmid-encoded HIV antigen Gag (pGag) 
comparing homologous prime-boost intradermal (i.d.) electroporation (EP) and 
intramuscular (i.m.) injection. As mentioned, (section 1.4.2.3.2) i.m. injection is 
known to induce broad but rather weak immune responses in mice, while 
electroporation induces very robust responses. To date, studies of skin EP have 
mainly focused on antigen expression, antigen specific humoral immunity, induction 
of IFN-γ-producing CD8+ T cells, and protective efficacy to infection (248-253). 
There has been a lack of knowledge of CD4+ T cell responses, especially their ability 
to produce combinations of cytokines. Therefore, in paper I we wanted to 
demonstrate if skin EP enhances not only the magnitude of cytokine-producing 
antigen-specific CD4+ T cells but also their diversity. As CD4+ T cells are critical for 
inducing functional CD8+ T memory cells and long-lived antibody responses, they are 
most likely required for protective vaccines.  
 
CD8+ T cells producing multiple cytokines appear to correlate with control of viral 
replication. CD8+ T cells in patients with progressive HIV-1 disease secrete only IFN-
γ, while they in elite controllers are multi-functional, secrete multiple cytokines 
typically in combinations of IFN-γ/TNF/IL-2 (238, 254-258). IFN-γ is necessary for 
an efficient response, however not always sufficient to predict control of viral 
replication used as a single parameter. Also TNF can mediate control of intracellular 
infections and synergizes with IFN-γ to induce killing of pathogens. IL-2 on the other 
hand has little direct effector function but enhances the expansion of CD4+ and CD8+ 
T cells.(259) 
 Similar correlations have also been shown for CD4+ T cells. Highly-exposed 
seronegative individuals such as commercial sex-workers appear to be in a state of 
HIV-specific immune activation, with HIV-specific CD4+ T cells that may correlate 
to protection (260-262). Hence, it is possible to induce these protective CD4+ T cells 
without infection. Also elite controllers are associated with proliferating, highly 
functional HIV-specific CD4+ T cells producing IFN-γ, IL-2 and/or TNF. In contrast, 
progressors are associated with HIV-specific CD4+ T cells that secrete only IFN-γ and 
fail to proliferate (239, 263-266). Furthermore, vaccine efficacy to other diseases than 
HIV-1 has been observed to correlate with their induction of polyfunctional T cells 
(259, 267).  
 
To evaluate the CD4+ T cell responses, we stimulated splenocytes from immunized 
mice with Gag peptide pool, OVA peptides (negative control) or media alone, for 6 
hours. We then stained the cells and used multicolor flow cytometry and applied a 
boolean gating strategy to detect single CD3+CD4+ cells producing combinations of 
IFN-γ, TNF, and IL-2. Additionally, in parallel assays we evaluated the quantity of 
produced IFN-γ by ELISPOT. Immunization with pGag by EP, compared to i.m. 
injection, significantly increased both the quantity of IFN-γ (Figure 1B, paper I) and 
the number of CD4+ T cells being double or triple cytokine producers.(Figure 1C, 
paper I) The results were consistent in both inbred BALB/c and C57Bl/6 mice. These 
results imply that EP not only enhances the magnitude but also the polyfunctional 
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quality of the CD4+ T cell responses. 
  
Additionally, to study CD8+ T cell responses, we stimulated splenocytes for 6 hours 
with a library of clade C Gag peptides (a p55 Gag peptide pool with 121 overlapping 
15-mers) and for the BALB/c mice immunodominant Gag peptide (AMQMLKDTI) 
to a defined H2-Kd epitope. Responses were evaluated using IFN-γ ELISPOT. In 
BALB/c mice, we could observe increased IFN-γ production by CD8+ T cells in EP 
group compared to the i.m. group in response to both clade C Gag peptides and 
AMQMLKDTI (Figure 2A, paper I). However we could not observe IFN-γ 
production above background levels in the C57Bl/6 mice (data not shown). The lack 
of detectable response is probably due to an inability for the cells to process the 15-
mer peptides in the peptide pool and present them in the MHC class I complex during 
the restimulation. Shorter peptides, such as 9-mers, can bind directly to the MHC 
class I complex (248), which could have facilitated the stimulation. BALB/c mice 
have been observed to respond to the immunodominant clade C gag peptide 
AMQMLKDTI, which binds H2-Kd. Stimulation with this peptide triggered CD8+ T 
cell responses from BALB/c mice also in this study. However, there is no such 
defined epitope for C57Bl/6 mice. 
 
 Finally, antigen-specific total IgG antibodies were detected by anti-p24Gag 
ELISA. We could observe that EP immunization induced two-fold higher IgG anti-
p24 titers compared to i.m. injection. The results were consistent in both inbred 
BALB/c and C57Bl/6 mice.(Figure 2B, paper I) 
 
In conclusion, our data showed that homologous prime-boost skin electroporation 
immunization induces robust and diverse immune responses. It provokes both 
humoral and cellular immunity with highly functional CD4+ T cells. As shown by 
others, it is also likely that these CD4+ T cells support CD8+ T cell functionality.  
 These results further strengthen the advantages that electroporation has over 
standard needle-based injections. It induces more robust and diverse immune 
responses using smaller volumes and lower doses of antigen. This is thought to, at 
least partly, be due to better cellular up-take of the DNA. This advantage may be even 
more pronounced in larger animals than mice, as the efficacy of i.m. injection is not 
only dependent on the vaccine concentration but also the injected volume. The 
standard injection volume in the mouse tibialis anterior muscle in DNA vaccination is 
50µl. This volume exceeds the fluid capacity of the muscle, leading to swelling and 
pressure that facilitates the cellular uptake of the DNA vaccine. When this the 
concentration of the DNA vaccine is kept the same but the volume is decreased to 5µl, 
the cellular uptake of DNA is diminished and both the antibody titers and T cell 
responses are substantially decreased (268). Similarly, the immunogenicity is higher 
when the vaccine is delivered into a small muscle such as the tibialis anterior rather 
than a larger muscle such as quadriceps femoris. Simplistic calculations comparing 
the size of the mouse calf with the human upper arm, show that the cross section of 
the human arm is about 900 times larger than the mouse leg. That implies that we 
would need to inject almost 45 liters into the human deltoideus to reach the same 
effect. It is highly unlikely that humans would approve of such a scaled up version.  
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4.2 Adjuvant properties of plasmid-encoded flagellin 
 
TLR ligands are now included as adjuvants in various vaccination strategies. There 
are also adjuvants and vaccines that are empirically successful, which only recently 
have been shown to function through TLRs. For example; the so-called Coley's toxin, 
a mixture of bacterial cell lysate used since 1893, has it response mediated through 
TLR9. Commonly used vaccines such as BCG-SSI, Influvac, and Typhim contain 
TLR ligands inducing a Th1 response. The live attenuated viral yellow-fever vaccine 
17D activates DC subsets via TLR2, TLR7, TLR8 and TLR9 and elicits response 
involving IL-12p40, IL-6 and IFN-α, resulting in a mix of Th1/Th2 cytokine profile 
and antigen-specific CD8+ T cells (188, 269). The TLR5 agonist flagellin is a well-
established adjuvant in protein-based vaccines, used since 1998 (270, 271). As a 
polypeptide adjuvant it elicits a robust humoral immunity also when used in very low 
concentrations and prior immunity to flagellin does not impair the response (271, 
272). Since flagellin is one of the few TLR agonists possible to use in a DNA-
encoded form, it is a very appealing adjuvant in plasmid DNA vaccination. 
 
In paper II we evaluate the adjuvant properties of plasmid-encoded flagellin (pFliC) 
when administrated through three routes representing different tissue compartments: 
mucosal (intranasal, i.na.), systemic (i.m. injection), and dermal (gene gun, g.g.). 
Even though i.m. injection is a well studied and efficient route of administration, it 
may not always be the most adequate, especially not when a mucosal immunity is 
requested. 
 In this study we can conclude that pFliC(-gly) increases both humoral and 
MHC Class I-dependent cellular immunity when co-delivered with the model antigen 
pOVA through all three routes (Figure 2 and 4A, paper II). Furthermore, it also 
induces mucosal antibody responses and MHC Class II-dependent cellular responses 
when delivered mucosally (Figure 3 and 4B, paper II).  
 Since we could show that pFliC promoted both cellular and humoral mucosal 
immunity we decided to test its effectiveness when delivered together with the 
clinical plasmid antigen gp160 (pgp160Lfai/pRev) in a heterologous plasmid prime-
protein boost setting. This approach was chosen because it has been observed that 
heterologous prime-boost vaccine regimes can be more immunogenic than 
homologous prime-boost(273). Here we could again show that intranasal (i.na.) 
immunization is dependent on the delivery lipid N3, which we believe protects the 
DNA vaccine from degradation. However adding pFliC further enhanced the 
production of total IgG in serum (Figure 5B, paper II) and both enhance the 
production of IgG1 and IgG2a and sustained it to later time points (Figure 5C, paper 
II). Similarly, addition of pFliC enhanced the titers of IgA in nasal washes (Figure 
6A, paper II). The IgA was additionally shown to be reactive to clade A and B and 
slightly to clade C (Figure 6B, paper II). To further study the quality of the antibody 
we did B cell epitope mapping against a gp160 peptide epitope library. The groups 
immunized with plasmid gp160 with N3 and boosted with recombinant gp160 with 
L3B exhibited clear reactivity against gp160 epitopes. Again, addition of pFliC 
improved the response by expanding the detectable populations by five, after 
excluding one new reactive site because of slight similarities between FliC and the 
region of increased reaction. 
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The adjuvant effect of polypeptide flagellin is mainly due to its high affinity for TLR5 
(274, 275). However soluble flagellin can also elicit NLRC4 mediated generation of 
inflammasome cytokines. Vijay-Kumar et al. have shown that soluble flagellin 
enhances production of anti-OVA antibodies in both TLR5 KO and NLRC4 KO mice 
following i.p. immunization. In mice deficient of both TLR5 and NLRC4 however, 
the antibody production is totally abrogated. This indicates that either receptor is 
sufficient for humoral responses. In the TLR5 KO mice, flagellin failed to induce 
release of cytokines other than IL-18, indicating that IL-18 plays an important role in 
antibody induction in these mice. In contrast to pro-IL-1β, pro-IL-18 is stored 
intracellularely and is not in need of a priming signal. NLRC4 KO mice on the other 
hand produced normal levels of all studied cytokines except IL-1β and IL-18 (75, 
276). As both receptors can be sufficient for humoral responses, it is possible that the 
involvement of TLR5 and NLRC4, respectively, can vary depending on the 
immunization site and cell type, as the expression pattern of these receptors differs 
between tissues. Additionally, not all cells respond in the same way to NLRC4 
activation. The immunogenicity can for example differ depending on whether the cell 
undergoes pyroptosis or not. How soluble flagellin is getting into the cytoplasm is 
unknown. It is likely to occur in limited rate, and NLRC4 is possibly activated to a 
higher degree using DNA vaccination. The plasmid-DNA encoded FliC used in 
paper II is transcribed into a protein equipped with a leader sequence and should be 
secreted. However, on its way out of the cell some of it may retrotranslocate from the 
ER into the cytosol where is could activate NLRC4/Naip5. It is therefor possible that 
its adjuvancy is due to a combination of TLR5 and NLRC4 signaling, and it may 
differ from the result of immunization with peptide flagellin. Flagellin has previously 
been shown to induce different responses depending on in which form it is 
administered. The response to soluble recombinant flagellin following systemic 
administration has been shown to be predominantly Th2, while in contrast, when FliC 
is administered during subsequent infection with/bound to S. typhimurium or 
produced by a plasmid DNA as an adjuvant, it enhances Th1 responses (192, 277, 
278).   
 
To determine if secreted pFliC(-gly) protein produced from pFliC vectors could 
activate TLR5, we applied culture supernatants from pFliC(-gly), pFliC(-gly)Δ34 
transfected 293 cells, or recombinant FliC protein to alveolar macrophages from 
B57BL/6 or TLR5 deficient mice. Both full-length and D34 secreted FliC(-gly) 
polypeptides were able to activate B57BL/6 macrophages to produce TNF, but not 
macrophages from TLR5 deficient mice, indicating that it can signal through TLR5 
independently of NLRC4. To evaluate NLRC4 activation we used an in vitro 
retroviral lethality screen assay. This assay detects the ability of macrophages, B10R 
cells, virally transduced with genes expressing various flagellin constructs as well as 
GFP to undergo pyroptosis in response to our secreted form of pFliC. GFP positive 
cells are taken as evidence of a lack of NLRC4 activation while GFP negative cells, 
relative to controls, are taken as evidence of NLRC4 activation. As positive control 
we used cytoplasmic flagellin (pcFliC(-gly)), which lack the leader sequence and 
remains in the cytosol. In this simple set-up, pFliC(-gly) seems to kill the cells as 
good as pcFliC(-gly). As negative control we used both secreted and cytoplasmic FliC 
with the NLRC4-activating tail deleted (Δ34c). These do not kill the cells, indicating 
that the cell death is NLRC4 dependent.  
 The transduction rate of is low in 293T cells however it is even lower in B10R 
cells, which is most likely because of poor packaging efficacy of the plasmids when 
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they contain flagellin inserts. Some plasmids do not package easily, an IRES 
sequence for example is known to drastically reduce packaging efficacy.((279)) 
However, we have repeated this experiment multiple times with the same results and 
have confidence in these results. 
 We do not know if our in vitro observations also hold true in vivo. However, if 
they did it would suggest that the some of the pFliC(-gly) in the immunization 
remains in the cytosol after transcription instead of being secreted by the Golgi-ER 
pathway. If so, it may activate the NLRC4 inflammasome, thereby affecting the 
immune response and the adjuvant properties of flagellin. This occurs when using 
peptide flagellin (276), and is likely to happen also with plasmid flagellin. The 
question is what impact the inflammasome activity and subsequence secretion of 
cytokines such as IL-1β and IL-18 has on the adjuvancy of pFliC and how it skews 
the immunity. It has been observed that IL-1-family cytokines (IL-1α, IL-1β, IL-18 
and IL-33) have strong mucosal adjuvant potential and a propensity to promote Th1-
like responses (280). Inflammasome dependent IL-1β, is further known to favor Th17 
polarization in infections such as Legionella pneumophila and Schistosoma mansoni 
and absence of IL-1 often leads to decreased numbers of cells producing IL-17 and 
IFN-γ (281, 282). Furthermore, IL-1β can promote T cell proliferation and contribute 
to maturation of dendritic cells (281). Supporting the theory of inflammasome 
induced Th17 responses, NLRP3 activation by uric acids induces Th17 responses(52). 
IL-17 plays an important role against infection especially in mucosal tissues, 
promoting epithelial regeneration, recruiting neutrophils, promoting macrophage 
recruitment and survival, stimulating production of proinflammatory cytokines and 
antibacterial peptides from both immune and non-immune cells. Furthermore it 
enhances the capacity for CD4+ T cells to produce IL-2 and enhance proliferation of 
both T cells and Tregs (163). Because of this Th17 cells are likely to be important for 
defense against for example HIV-1, and HIV-1 long-term non-progressors have also 
been reported to have greater numbers of Th17 than progressors. IL-18, as mentioned 
(section 1.1.2) can amplify different cytokines depending on its cytokine milieu and 
hence favor different responses. NLRC4 activity can mediate non-cognate IFN-γ 
release during Salmonella typhimurium infection. Released IL-18 drives IFN-γ -
production by memory CD8+ T cells, as well as NK and NKT cells (283). This could 
affect the frequency of IFN-γ observed in paper II.  
 Unexpectedly, the well-studied NLRP3 inflammasome activating adjuvant 
Alum induces strong Th2 responses. It is unknown why, but can of course be due to a 
differently balanced immune response. Additionally, the Th2 skewing has been seen 
to by independent of inflammasome activation (284, 285). Furthermore, Alum has 
successfully been combined with certain TLR agonists. When Alum is combined with 
the TLR4 ligand monophosphoryl lipid A (MPL) in the licensed adjuvant AS04 
(GlaxoSmithKline), it results in a predominantly Th1 response(286). MPL is a 
compound, derived from Salmonella minnesota LPS, that is less toxic than LPS, 
possibly because it only signal through the TRIF-TRAM pathway while LPS signal 
through both MyD88-TIRAP and TRIF-TRAM (287).  
 In paper II we did not have the possibility to assay IL-17, however both the 
production of IFN-γ following immunization through all three routes as well as the 
CD4+ T cell response profile indicates that pFliC(-gly) promotes a Th1 response 
rather than a Th2 response. Apparently pFliC does not entail the same problem with 
Th2 skewing as Alum. We cannot say how much of the adjuvant effect that is due to 
signaling through TLR5 vs. NLRC4 even though we can conclude that both systems 
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can be activated by pFliC(-gly). Some of these questions could be answered by 
immunizing with a plasmid DNA-vaccine combined with full-length pFliC and pFliC 
Δ34C adjuvants in wild type, TLR5-, NLRC4-, Caspase-1-, IL-1β-, IL-18-, IL-1/IL-
18-, IL-1βR-deficient mice. 
 
It is interesting that we can observe IgG and IgA in mucosal compartments following 
i.na., but not i.m. or g.g immunization. Mucosal immunization is well known to elicit 
stronger mucosal immune responses than systemic immunization, also at different 
mucosal sites than the immunization site. This is thanks to the mucosal-associated 
lymphoid tissue (MALT), a highly compartmentalized immunological system that is 
anatomically separated from the systemic immune apparatus. I.na. immunization is 
however known to induce more widely disseminated mucosal IgA and systemic IgG 
compared to other mucosal immunization routes e.g. oral, rectal and vaginal(288). 
What is more difficult to explain is how flagellin has these special adjuvant effects 
only when delivered mucosally. One mechanism of how flagellin could act as a 
mucosal adjuvant involves the CD103+ dendritic cells in the lamina propria in the 
small intestine. These cells express high levels of TLR5 and respond directly to 
flagellin. Immunization with soluble FliC induces TLR5 dependent selective 
recruitment in of CD103+ DCs to the mesenteric lymph nodes, where it primes for 
Treg induction and promotes switch of naive B cells from IgM IgD to IgA (289, 290). 
How flagellin drives the migration of CD103+ DCs is unknown, but it probably 
involves binding of TLR5, since these cells express very high levels of TLR5 
compared to macrophages and DCs in other tissue compartments (231). However, this 
recruitment CD103+ DCs follows both i.p. and s.c. flagellin immunization, indicating 
that this phenomenon is not restricted to mucosal immunization (290). The discovery 
of the NLRC4/Naip5 inflammasome system in sensing flagellin indicates that these 
previous observations may also be influenced by these innate immune receptors.  
 
4.3 NLRC4 induced pyroptosis 
 
The previous two papers were focused on pre-clinical vaccine studies. In paper II we 
realized that activation of the NLRC4 inflammasome can contribute to the adjuvant 
effect of pFliC. Therefore, in paper III the focus was shifted to studies on flagellin-
induced inflammasome activation. 
 
Most inflammasome studies have focused on the involvement of the NLRP3 
inflammasome. Mainly because it is activated by a large array of stimuli and is 
involved in many different conditions which allows medical researchers from diverse 
fields to find a tie-in. However, there are still more inflammasome complexes being 
discovered and the individual importance of the NLRP3 inflammasome in 
inflammatory responses and pathologies remains to be seen. 
 To activate the NLRC4 inflammasome, it is possible to infect macrophages 
with whole bacteria expressing agonist(s), transduce macrophages with retroviral 
vectors expressing flagellin, or transfect macrophages with recombinant flagellin 
protein. However, all of these techniques activate other cell signaling pathways in 
addition to NLRC4 inflammasome activation. The aim of paper III was to establish a 
system to induce expression of C34, the NLRC4 activating region of flagellin, 
without triggering other cell signaling pathways. We wanted to be able to activate the 
NLRC4 inflammasome alone, to then add back different forms of stimuli to 
understand how they affect the system. To establish such a system, a mouse 
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macrophage cell line, B10R, was stably transduced with a Tet-ON based retroviral 
vector expressing the C-terminal 34 or 19 amino acids of S. typhimurium (FliC) fused 
to EGFP. Expression of C34-EGFP or control C19-EGFP was controlled by the 
addition of the tetracycline analogue Doxycycline (Dox). 
 
It has previously been shown that the expression of NLRC4 is independent of a 
priming signal (59). Using our Dox-inducible system we can now further conclude 
that a biological function of NLRC4 activation, pyroptosis, can be activated 
independently of LPS priming. Additionally, LPS priming does not affect the degree 
of pyroptosis (for 3 and 18 hours).(Figure 1C-E, I-J paper III) However, when 
priming is applied, this allows for the expression of pro-IL-1ß which is then processed 
and released as processed IL-1β with NLRC4 inflammasome activation. (Figure 1G-
H, paper III). 
 Interestingly, the fact that pyroptosis is unaffected by TLR priming and 
associated pro-survival signals activated through NF-κB, suggests that this type of 
cell death is "separate from" or "above" NF-κB in a signal hierarchy. The pyroptosis 
system appears to function in this way and may be a last resort for an infected cell to 
take if an infection is ‘perceived’ to be present in the cytoplasm. Pyroptotic 
independence from the NF-kB system is likely of great importance since a variety of 
pathogens attempt to interfere with immune defense by promoting NF-κB-dependent 
pro-survival signals. Furthermore, our observations of pyroptosis occurring 
independently of LPS priming would ensure pathogen recognition and successful 
pyroptosis also in cells expressing TLR4 but unresponsive to LPS stimuli. This would 
be of special importance in hyporesponsive compartments as the gut, where the cells 
are anergic to TLRs (see section 4.6) Indeed, it has been observed that prolonged LPS 
exposure of macrophages and dendritic cells leads to LPS tolerance and 
downregulation of TLR4 (291). We, as well as others have observed that a LPS 
priming signal simultaneous with, as well as too long prior to (18 hour prime) 
inflammasome stimuli in our immortalized BMMs fails to induce IL-1β release (data 
not shown). Additionally, a requirement for an inflammasome priming signal during 
infection could make delayed activation of host-defense a handicap to successful 
defense.  
 The ability to respond without priming is however especially important in the 
intestine. Resident intestinal mononuclear phagocytes (iMPs) are anergic to TLRs 
(292-294) and have down-regulated levels of both mRNA and protein for multiple 
innate response molecules as well as adapter molecules such as MyD88 and 
TIR.(295) In contrast to monocytes and BMDMs, unstimulated iMPs constitutively 
express pro-IL-1β, and have been observed to undergo NLRC4 dependent pyroptosis 
and in fact also release IL-1β independent of priming in response to S. typhimurium. 
Induction of the NLRP3 inflammasome using LPS and ATP on the other hand, does 
not induce IL-1β processing, consistent with the lack of NF-κB-mediated 
upregulation of NLRP3 (294). Since NLRC4 is thought to exclusively recognize 
components from the Type III secretion system and flagellin from pathogenic 
bacteria, this system ensures that pathogens are discriminated from the commensal 
flora and can respond rapidly also in a "tolerant" environment. 
 
To confirm that our observed cell death is pyroptosis, defined as caspase-1 dependent 
cell death, we transduced C34 cells with the cowpox virus serpin CrmA, inhibiting 
caspase-1 and -8. Expression of CrmA inhibited the cell death to base line levels 
(Figure 1F, paper III). However the capase-8 specific inhibitors cFLIP-long and 
39	  
cFLIP-short did not affect the cell death indicating that the cell death is dependent on 
caspase-1. Occasionally, cell death correlating with NLRP3-dependent processing of 
IL-1β is independent of caspase-1 (63). We feel this form of cell death is not to be 
defined as pyroptosis but rather apoptosis in a primed setting with parallel 
inflammasome activity. 
 
The outcome of NLRC4 activation is most likely affected by the strength and length 
of stimulation. Activation of a stress response pathway called autophagy is probably 
among the first pathways activated upon infection. Stress management, if successful 
would allow cell survival upon NLRC4 activation. However, in situations where 
activation is dominant these pathways, at best, would only slow down inevitable 
pyroptotic death. In our model pyroptosis occurs rapidly and a significant increase in 
cell death is seen already after two hours with a maximum after 24-32 hours. In 
comparison, etoposide-induced apoptosis in C34 cells is first observed at around eight 
hours. Some studies report that IL-1β secretion precedes pyroptosis (296, 297), 
however in our system these two responses occur simultaneously (Figure 1C-E, G-J, 
paper III). Additionally, both the IL-1β release and the pyroptosis are dose-
dependent to the amount of NLRC4 agonist (data not shown) For studies such as ours, 
a functioning inducible system is very beneficial, since we can control the time point 
of NLRC4 activation, agonist dose, and general persistence of the stimuli. 
Additionally we can study the outcome of cells after removing the stimuli. To remove 
whole bacteria after initial macrophage infection requires antibiotics, commonly 
gentamicin, which could possibly affect the inflammasome/pyroptosis system. To 
study the recovery of C34 cells after NLRC4 activation we Dox-induced cells 
followed by Dox removal by washing cells at various time points in a kinetic study 
over 24 hours. This data is not present in paper III but is presented here in this thesis. 
Agonist induction and cell death were examined at the indicated times after Dox 
removal and at 24 hours after Dox addition. When examining cell death at the 
indicated times, we found that it increased and correlated with agonist expression over 
time with a maximum at 24 hours. However, when Dox was removed at different time 
points after initial induction, we found that the amount of EGFP signal did not 
continue to increase compared to cells continually incubated in Dox (Figure 3A). 
Nevertheless, the cell death continued to increase also after Dox removal. Even the 
cultures that had only one hour of NRLC4 activation followed by Dox removal also 
reached almost maximum pyroptosis after 24 hours.(Figure 3B) These results could 
indicate that even a brief NLRC4 inflammasome activation could be a point of no 
return. In our system, after the agonist is detected in the cytoplasm, some cells die 
rapidly, and others slower. However, in cells only briefly Dox activated, the presence 
of persistent but low levels of agonist is still able to instruct nearly all responding 
cells (EGFP+) to undergo pyroptosis at the same frequency by 24 hours. To 
extrapolate these findings to an infectious model system, these results suggest that 
also lower doses of bacteria expressing NLRC4 agonists could induce pyroptosis in a 
susceptible cell if the infection and agonists persist.  
 
 
 
 
 
 
 
40	  
 
 
 
Figure 3. C34 cells eventually die even though the Dox is washed out at different time 
points. A. Viability. B. EGFP induction. 
 
 
4.4 Release of IL-1β 
 
As mentioned, IL-1β lacks a conventional secretion signal and is not released by the 
ER-Golgi secretory pathway. Generally speaking, when IL-1ß is released other 
leaderless cytokines and DAMPs, such as HMGB1 can be secreted simultaneously. 
Different release mechanisms have been reported and they are probably not mutually 
exclusive but influenced by the cell type, stimuli, and time. Proposed mechanisms are 
exocytosis of secretory lysosomes, release of membrane-delimited microvesicles as 
plasma membrane blebs (298-300), release of membrane-delimited exosomes formed 
by recycling endosomes (301), exocytosis of autophagosomes or autophagolysosomes 
(29,302-305). Pannexin-1 pore formation (306-308) or direct release by cell death 
(116, 130). 
 
Autophagy, the stress response responsible for degradation of dysfunctional cellular 
components, can affect IL-1β release in two ways. In a context of the NLRP3 
inflammasome, baseline autophagy decreases the release of IL-1β. This is mainly due 
to the NLRP3 inflammasome's dependence on mitochondrial DNA and ROS, which 
during normal conditions is cleared by autophagy, thereby hampering or delaying 
NLRP3 activation. Impaired or inhibition of autophagy leads to an accumulation of 
dysfunctional mitochondria leading to generation of ROS and release of 
mitochondrial DNA which augments NLRP3 inflammasome activity (302, 305, 309). 
Furthermore autophagosomes can control IL-1ß release by sequestering and 
degrading pro-IL-1β polypeptide and inflammasome components needed to process 
pro-IL-1ß (303, 309, 310). In contrast, autophagy induced by starvation or inhibition 
of mTOR (rapamycin) can act as a mechanism for IL-1ß secretion. Most produced 
pro-IL-1β is thought reside in the cytosol, however some of it is protected inside 
vesicles suggested to be autophagosomes (302-305). LPS treatment induces 
recruitment of IL-1β to autophagosomes and the autophagosome can either fuse with 
a lysosome and the IL-1β will be degraded, or it can be transported to the cell surface 
and the IL-1β released (303, 305). NLRC4 and NLRP4 negatively regulate autophagy 
by binding the autophagy component Beclin-1 which may be a way that activation of 
certain NLRs could release the brakes on IL-1ß production. Furthermore, NLRP4 
inhibits maturation of autophagosomes and thereby the fusion with lysosomes and 
hence degradation of content. In contrast, NOD1 and NOD2 directly induce 
B A 
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autophagy by recruiting the autophagy regulator Atg16L1 to phagosomes containing 
bacteria. Atg16L1 activation may be a specific pathway linking bacterial recognition 
and autophagy. Cells from Atg161 deficient mice undergo standard physiological 
activated autophagy but not bacteria-induced autophagy and produce more IL-1β in 
response to stimuli such as LPS. Not surprisingly, a consequence of Atg16L1 
deficiency is associated with the hyper-inflammatory condition Crohn's disease (304).   
 
In our system, the release of IL-1β correlates with pyroptosis (Figure 1G-J, paper 
III), indicating that cell lysis could be a mechanism of release. However the IL-1β 
ELISA that we used does not discriminate between the unprocessed and the active 
form of IL-1β. By using immunoblotting techniques to detect IL-1β in supernatants 
and lysates, we observe the presence of cleaved p17 IL-1β, but also remaining uncut 
pro-IL-1β.(Figure 1H, paper III) This indicates that the release of processed IL-1ß 
does not necessarily increase proportionally to pyroptosis. Interestingly, unprocessed 
pro-IL-1β released cells can also be inflammatory. It is not exclusively cleaved by 
caspase-1 enzymatic activity but can also be processed by neutrophil-derived 
proteases (311).  
 Hypothetically, it could be possible that in our system we would observe more 
processed IL-1β released if the cells went through a "slower" death. Unlike NLRP3, 
the absolute requirement for NLRC4 inflammasome function is not dependent on the 
inflammasome adaptor ASC. However, it has been observed that IL-1β processing is 
strongly diminished in its absence (312). The presence of ASC can also function in a 
negative feed-back loop to inhibit pyroptosis and favor IL-1β processing (313). Since 
most of our cells die with rather low levels of processed IL-1β, around 150 pg/ml, it is 
possible to speculate that the ASC levels are detectable, but low, and the death/IL-1β 
ratio may be possible to skew by over-expression of ASC.  
  Arguing against the idea of lysis-dependent release of IL-1β are studies where 
glycine is used to inhibit/slow NLRC4 and NLRP3-induced cell death but still allows 
cytokine release. However, researchers observing these phenomena have suggested 
that IL-1β could leak out through proposed pore-like formations in the cell membrane 
(130, 314). In experiments ongoing in our lab we are working to inhibit pyroptosis, 
without inhibiting caspase-1 enzymatic activity and thereby possibly influencing the 
release of processed IL-1β.  
 However, as mentioned, the mechanisms of IL-1ß release and pyroptosis are 
probably not mutually exclusive and may be strongly influenced by cell type, kinetics 
of activation, cytokine environment and type of infection. 
 
4.5 Involvement of mitochondria and ROS in NLRC4 inflammasome function. 
 
The activation of the NLRP3 inflammasome has been observed to be dependent on 
disrupted mitochondrial function, mitochondrial ROS production, K+ efflux and 
release of Ca2+ from the endoplasmatic reticulum (59, 62, 63, 302, 315). The study 
by Shimada et al. (63) established a working model by linking these three events. 
They could demonstrate that many NLRP3 activators disrupt mitochondrial function, 
as revealed by dissipation of the inner mitochondrial membrane potential, possibly as 
a consequence of K+ efflux and Ca2+ mobilization (315) upstream of inflammasome 
assembly. The disruption leads to mitochondrial ROS production and, furthermore, 
release of oxidized mitochondrial DNA (mtDNA) into the cytosol, where it acts as an 
agonist to promote NLRP3 inflammasome assembly (63). 
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Since we have the ability to study responses to NLRC4 inflammasome activation in 
absence of TLR activation or other additional stimuli, we wanted to study the role of 
mitochondria in this activation process and whether ROS is produced. 
 
From our first experiments we could conclude that NLRC4-induced pyroptosis is 
unaffected by ROS production since it was unaffected by ROS generating LPS 
priming. Our ongoing observations were confirmed along the way by Zhou and 
colleagues (62). Furthermore, we observed that pretreatment of C34 cells with the 
general antioxidant N-acetyl-cysteine (NAC) or the organelle-specific antioxidants 
MitoQ (mitochondrial) or the NADPH oxidase (Nox) inhibitor VAS-2870 prior to 
Dox addition does not affect pyroptosis.(Figure 4) We have not yet studied release of 
IL-1β during inhibition of ROS. However, its processing could possibly be 
diminished with antioxidant use since ROS may be required for recruitment of ASC 
(62).  
  
 
 
 
Figure 4: Pre-treatment of C34s with antioxidants NAC, MitoQ or VAS-2870 does 
not affect NLRC4 induced pyroptosis  
 
When Dox-activating unprimed C34 cells, we did not observe production of ROS or 
nitric oxide (NO), although the cells were capable of such production after LPS 
stimuli.(Figure 3B-C, paper III) In macrophages, mitochondria and NADPH 
oxidases are thought to be the major sub-cellular sources of ROS production. In our 
experiments we used an assay that detects whole-cell ROS. It is conceivable that the 
source of ROS after LPS activation is the mitochondria as shown by West et al. (62, 
316).  The mitochondria, rather than NADPH oxidases, have been observed to be the 
source of ROS upon activation of the NLRP3 inflammasome, as macrophages lacking 
functional NOX1, NOX2 and NOX4 respond normally to NLRP3 stimulation(317, 
318). Here we use the term ROS to describe numerous species of reactive oxygen 
intermediates. In reality, several types of ROS species are formed during the process 
of oxidative phosphorylation used to generate ATP. In this process, O2 is reduced to 
H2O by a series of protein complexes (I to IV) to generate an H+ gradient which 
powers ATP synthesis by protein complex V. If complex I is inhibited, by for 
example the chemical rotenone, this “short-circuits” the process and leads to 
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increased ROS production. Our observed lack of ROS production during NLRC4 
activation and pyroptosis indicated to us that NLRC4 agonists apparently do not cause 
disruption of the mitochondria as NLRP3 agonists do. However, being curious we 
decided to investigate mitochondrial involvement in greater detail. 
 
To inhibit mitochondrial outer membrane permeabilization (MOMP) involvement in 
pyroptosis, we overexpressed the Bcl-2-like protein Bcl-xL in C34 cells. MOMP 
occurs during standard intrinsic apoptosis (section 1.2.1.1) and overexpression of Bcl-
2 and family members lead to partial closure of the voltage-dependent anion channels 
(VDAC) in the outer membrane of the mitochondria. This closure decreases 
mitochondrial membrane permeability and ROS production upon apoptotic challenge. 
Overexpression of Bcl-2 inhibits apoptosis associated with NLRP3 activation (63) 
and decreased IL-1β release after NLRP3 stimuli (62). However, in our system, over-
expression of Bcl-xL does not inhibit NLRC4-induced pyroptosis although it 
inhibited etoposide-induced apoptosis.(Figure 4A-B, paper III) 
 
To evaluate the stability of the inner mitochondrial membrane potential during 
NLRC4 activation we loaded the cells with the fluorescent dye TMRE which is 
specifically taken up by mitochondria and held inside dependent on a stable inner 
membrane potential. Decreases in inner membrane potential can be measured as a 
decrease in TMRE fluresence (Δψm) using flow cytometry. Dox-induction of the cells 
led to a slight, but still significant and reproducible decrease in Δψm. We then 
questioned whether this decrease was associated with pyroptosis. When inhibiting this 
slight decrease by suppressing inner membrane permeability with the compound 
Cyclosporin A (CsA), we could prevent the slight decrease in membrane potential but 
observed no difference in the degree or speed of cell death, indicating that NLRC4 
induced pyroptosis occurs without a need to dissipate the inner mitochondrial 
membrane potential.(Figure 4C-G, paper III) 
 It has been shown that the mitochondrial disruption observed after NLRP3-
triggering stimuli leads to release of oxidized mtDNA into the cytosol where it 
promotes NLRP3 activation (62, 63, 302). In unpublished experiments I performed 
quantitative RT-PCR to detect release of mtDNA from Dox-induced C34 cells, but 
the levels we observed were not above background (Figure 5). These results further 
support (indirectly) our observations that mitochondria likely remain intact during 
NLRC4 activation. 
 
 
Figure 5: There is no increased release of mitochondrial DNA from Dox-induced 
C34s compared to unstimulated cells. 
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While performing our experiments indicating that NLRC4 activation and pyroptosis 
occurred independently of standard mitochondria involvement, we tested whether we 
could observe cutting of the pro-apoptotic protein Bid. Generally, when Bid is cut 
during the activation of cell death pathways into a truncated form called tBid, this 
small form acts to promote MOMP opening and trigger apoptotic cell death(319). 
Analysis of Bid by immunoblot revealed an intact form in unactivated cells but we 
observed a cleaved tBid form upon triggering pyroptosis (Figure 6). However, while 
searching the extensive cell death literature we found that this phenomenon has been 
observed before in situations of regulation of NOD1 and NOD2 signaling and does 
not absolutely implicate mitochondria involvement in cell death pathways (320). 
Indeed, this observation may mean that macrophage pyroptosis is more of 'type I' cell 
death (section 1.2.1.2).  
 
 
 
Figure 6: NLRC4 activation induces Bid cleavage.  
 
Potassium (K+) efflux from cells is associated with, and may be a necessary factor to 
activate the NLRP3 and NLRP1 inflammasomes. Indeed, lower intracellular K+ is 
thought to be what triggers decrease in Δψm in mitochondria and facilitates release of 
oxidized mtDNA. The involvement of K+ in NLRC4 activation is less clear. We have 
shown that the NLRC4-induced pyroptosis is independent of decreases in Δψm, and 
could thereby speculate that it would be independent of K+ efflux. However, 
pyroptosis and IL-ß processing may not be absolutely linked. It may be possible that 
IL-1β processing could be diminished by inhibiting K+ efflux during inflammasome 
activation as physiological levels of K+ inhibits ASC assembly. ASC can be co-
immunoprecipited together with NLRP3 (and NLRC4) in normal K+ conditions but 
not when K+ efflux is inhibited by high extracellular K+ indicating that K+ could 
influence the NLRC4 inflammasome (58).  
 I have attempted to experimentally address these issues by inducing NLRC4 
activation in C34 cells in various concentrations of extracellular K+. However, I have 
seen no difference in the degree of pyroptosis using various K+ concentrations (data 
not shown). However, our C34 cells cannot cope with as high concentrations of K+ as 
is used in other studies. 
 
In conclusion, activation of the NLRC4 inflammasome clearly differs from the 
NLRP3 inflammasome as it does not require ROS production or involvement of the 
mitochondria in the same fashion. Furthermore, activation of the NLRC4 
inflammasome is not associated with generation of ROS, NO or release of mtDNA. 
These findings illustrate the numerous differences between the NLRC4 and the 
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NLRP3 inflammasomes, and can partly explain why both these inflammasomes are 
activated while recognizing the same pathogen in the same cell. 
 
4.6 When would cells find enough NLRC4 stimuli without activation by other 
PAMPs? 
 
We have shown that NLRC4 activation is independent of TLR priming and ROS. But 
would such a situation arise in vivo? In all proposed systems NLRC4 activation would 
nearly always happen with surface TLR activation. So when would a cell find enough 
flagellin to activate the NLRC4 inflammasome, without additional TLR stimuli or 
ROS production through TLR activation? 
 In commonly used cell systems using in vitro differentiated macrophages 
activation of the NLRC4 system likely occurs at the same time as stimulation through 
TLRs which are still expressed by these cell types such as TLR4. In this context these 
models we would predict that NLRC4 and TLR signaling would always occur hand in 
hand. 
 
However, we could imagine certain scenarios in which NLRC4 activation may occur 
with TLR engagement but cells have a “tolerized” TLR signaling pathway. 
Alternatively, TLRs are not engaged due to different cellular compartmentalization, 
lack of expression. Or maybe even standard expression and signaling however the 
cells may have altered metabolic functions and do not respond to produce ROS in the 
same fashion. Here, I discuss these possibilities in more detail. 
 The cells in tissues such as the intestine need to prevent harmful responses to 
commensal bacteria. The epithelia in the gut, as well as in the kidney and airways, is 
polarized with the apical side towards the lumen, exposed to microbiota and nutrients, 
and the basolateral side protected from such stimuli. Most TLRs expressed by 
epithelial cells, including TLR5, are located on the basolateral side. Hence, TLR5 is 
only activated if the epithelial is disrupted (231, 321, 322). As most chronic infectious 
bacteria, such as H. pylori, is known to be non-invasive, it will not activate TLR5. 
Because of this polarization, it is possible that non-invasive bacteria could activate 
NLRC4 in epithelial cells without TLR5 recognition. Furthermore, the epithelial TLR 
expression pattern is altered in different parts of the gut. TLR2 and TLR4 are 
expressed in low levels by intestinal epithelial cells, TLR3 is abundantly expressed in 
small intestine and colon while TLR5 is predominantly expressed in the colon (322). 
In this way the selective expression of TLRs may create scenarios in which an enteric 
pathogen could possibly activate NLRC4 without activating standard TLR responses. 
 
Also the intestinal phagocytes have altered TLR expression. The already mentioned 
(section 4.3) resident iMPs in the gut are anergic to TLRs and may encounter NLRC4 
inflammasome stimuli without the ability for TLR signaling.  
However, a subpopulation of CD11c+ DC in the small intestine express high levels of 
TLR5, but not TLR4, and respond to flagellin even though they are unable to respond 
to TLR4 (231).  
 If ROS production in iMPs is dependent only on TLR signaling, a scenario of 
TLR-independent NLRC4 activation is likely to occur without generation of ROS, as 
mimicked by our system. If so, we could hypothesize that if pyroptosis occurs in an 
iMP that released HMGB1 should be in chemotactic all-thiol form. It therefore may 
be possible that pyroptotic iMPs cells could recruit more neutrophils to the site of 
infection than circulating macrophages during inflammasome activity. NLRC4 and 
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neutrophil influx in the intestine is an essential part in the defense against S. 
typhimurium. Even though IL-1β accounts for this influx to a great extent (294, 323), 
chemotactic HMGB1 may also play an unstudied role. 
 
To avoid inflammatory overreactions, TLRs are downregulated upon prolonged 
stimuli. Endotoxin tolerance is a well known phenomenon where prolonged LPS 
stimuli induces downregulation of TLR4 at mRNA level as well as internalization of 
the receptor (291, 324). Similarly, prolonged flagellin exposure to epithelial cells 
blocks activation of NF-kB and MAPK signaling pathways and results in 
internalization of TLR5. This flagellin tolerance is a rapid process that occurs within 
1-2 hours after flagellin stimuli, and the cells require more than 24 hours to recover 
(74). The TLR5 mRNA expression is also downregulated by other TLR agonists such 
as LPS and CpG (325). This form of tolarization may lead to establishment of the 
pathogen and chronic infection. In those cases, the ability to induce NLRC4 response 
in TLR hyporesponsive cells could be of importance. 
 
Cells ability to respond to TLR stimuli can also be affected by surrounding cytokines. 
Th2 cytokines such as IL-4 and IL-13 downregulate TLR3 and TLR4 on mRNA level 
leading to functional impairment (326). IL-10 has also been suggested to decrease 
TLR expression since mice lacking IL-10 are hyperreactive to LPS (327) and 
blocking IL-10 leads to severe colitis in mice (323). Additionally, autocrine IL-10 
appears to be involved in the "exhaustion" of DCs and blocking IL-10 enables DC to 
remain in mature state rather than get exhausted (328). We have induced pyroptosis in 
C34 cells stimulated with IL-10 and could observe no decrease in death, indicating 
that IL-10 does not affect NLRC4 activation (data not shown). However, it is possible 
that in a context of LPS priming together with IL-10 that less ROS could be produced 
affecting HMGB1 isoforms released by pyroptosis. This remains to be tested.  
 
The ability of cells to undergo pyroptosis without any requirement for priming can 
also be important to sidestep bacterial evasion mechanisms. There are situations 
where bacterial evasion mechanisms could affect TLR signaling and ROS production. 
As the flagellin polypeptide activates TLR5 and NLRC4/Naip5 through different 
functional domains bacteria could possibly have a mutated flagellin to confer TLR5 
activation while the inflammasome activating region is still intact. Indeed, point 
mutations of flagellin at I411A abolish motility and TLR5 activation, however it can 
still activate cells through NLRC4(329). Alternatively, NLRC4 can recognize non-
flagellated bacteria through components of the T3SS/T4SS (330, 331).  
 Additionally, some bacteria avoid clearance by the host by interfering with 
ROS by neutralization or inhibiting the generation. However, they usually target the 
NADPH oxidation chain rather than mitochondrial ROS production.(332) 
 
Very low levels of flagellin are required to activate cells through TLR5. The 
described mechanisms to avoid TLR signaling and generation of ROS do not 
completely abrogate ROS production but rather decrease is. However, this decrease 
may still have an effect on the isoform of HMGB1. Low levels of stimuli may induce 
levels of ROS that is low enough to be absorbed by stress-induced adaptation 
programs such as autophagy. As mentioned, the ROS dependent NLRP3 
inflammasome can be hampered or delayed by basal autophagy clearing out low 
levels of ROS. In the same way, it is possible that autophagic activity inhibits the 
oxidation of HMGB1 at low levels of ROS (section 4.4). 
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 Admittedly, these are only speculations and there is yet not enough known 
about the expression and involvement of the NLRC4 inflammasome in different 
situations of infection to know when ROS is produced, where ROS is produced, and 
how much ROS is produced. 
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CONCLUDING  
 
The aim with this thesis was to study approaches to improve the efficacy of DNA 
vaccines. We have evaluated different delivery routes and methods as well as the 
adjuvant properties of plasmid encoded flagellin. As it turned out, the molecular 
mechanisms behind the adjuvancy of flagellin were too exciting not to study and this 
curiosity grew into a project in itself. By establishing our inducible system we also 
developed a great tool to study the effect of different additional stimuli on the NLRC4 
inflammasome activity. 
 
Our main findings demonstrate:   
• Homologous prime/boost DNA vaccinations using skin EP enhances not only 
the magnitude of cytokine-producing antigen-specific CD4+ T cells, but also 
increases the functional heterogeneity (paper I). 
• Plasmid-encoded flagellin enhances both cellular an humoral immunity when 
delivered i.na., i.m. or g.g. with additional mucosal immunity when delivered 
i.na.(paper II). 
• NLRC4-induced pyroptosis is unaffected by LPS priming, ROS production, 
and standard mitochondrial involvement (paper III). 
• The functional isoform of HMGB1 released during pyroptosis is affected by 
priming and correlates with ROS production (paper III). 
 
To improve the strength of DNA vaccinations, a combination of an appropriate 
adjuvant customized to the antigen, recipient, immunization site and an effective 
delivery method will be required. Furthermore, the delivery route must be chosen to 
induce desired immunity at the infection site. Plasmid-encoded flagellin is a good 
adjuvant candidate, especially when mucosal immunity is desired. Its ability to induce 
a broad immune response through activation of both TLR5 and NLRC4 may mimic a 
"natural" inflammatory environment which could have advantages over other 
adjuvants to induce protective immunity. We have further shown the benefits of skin 
electroporation as a delivery method inducing both robust and diverse immune 
responses. However, mucosal immunization may be required for sufficient mucosal 
immunity. 
 
Our studies, along with others, highlight the differences between inflammasome 
platforms. Differences in how inflammasomes are triggered can explain why a 
pathogen may have the ability to activate multiple inflammasomes. Furthermore, with 
our increased understanding of the cellular differences associated with how 
inflammasomes work, we may be able to better understand differences in 
inflammasome outcomes. 
 Although it has been previously shown that pyroptosis is inflammatory 
beyond IL-1β and IL-18 release, our results reveal an increased understanding of the 
metabolic state of pyroptosis and how changes induced by priming likely alter the 
body's perception of pyroptotic cell death. Although experimentally challenging, we 
look forward to a better understanding of the relationship between other innate 
immune receptors and metabolism in the inflammasomes roll in host-defense and 
pathology. 
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